{ "schemaVersion": "deck-intelligence.v1", "id": "019de076-f978-76c3-9c95-6b6ce7102162", "slug": "c02a1d1cb7557bc430cc8dc61cd27097", "title": "CG Oncology | IPO Presentation Deck | 45 slides", "subtitle": "CG Oncology · 2024-03", "author": "CG Oncology", "date": "2024-03-01 00:00:00", "pageCount": 45, "kind": "pitchdeck", "orientation": "landscape", "aspectRatio": 1.7761332, "document": { "id": "019de076-f978-76c3-9c95-6b6ce7102162", "slug": "c02a1d1cb7557bc430cc8dc61cd27097", "title": "CG Oncology | IPO Presentation Deck | 45 slides", "rawTitle": "CG Oncology | IPO Presentation Deck | 45 slides", "authorId": "cg-oncology", "authorName": "CG Oncology", "authorDisplay": "CG Oncology", "kind": { "slug": "pitchdeck", "label": "Pitch deck" }, "sourceType": { "slug": "investment_bank", "label": "Investment bank" }, "fileName": "2024-03__cg-oncology__ipo__c02a1d1c.pdf", "sourceUrl": "https://www.slidebook.io/company/cg-oncology/presentation/c02a1d1cb7557bc430cc8dc61cd27097/", "sourceDate": null, "presentationDate": "2024-03-01 00:00:00", "ingestedAt": "2026-04-30 22:16:26.845275+00", "status": "ready", "pageCount": 45, "orientation": "landscape", "aspectRatio": 1.7761332, "targetCompany": null, "targetTicker": null, "metadata": { "corpus": "slidebook", "industry": "biotechnology", "local_root": "/Users/miguelsuredasuau/Desktop/lalalalla/_scrape/slidebook/decks/2024-03__cg-oncology__ipo__c02a1d1c", "image_width": 1920, "image_format": "jpg", "deck_type_raw": "IPO Presentation Deck", "deck_type_slug": null, "source_url_pattern": "https://www.slidebook.io/company/{company_slug}/presentation/{deck_id}/" } }, "coverage": { "pageCount": 45, "pagesIndexed": 45, "pagesWithImages": 45, "pagesWithMetadata": 45, "imageCoveragePct": 100, "metadataCoveragePct": 100, "componentCount": 224, "chartCount": 5, "metricSlides": 0, "toolMatches": 28, "documentToolMatches": 0, "frameworkMatches": 18, "arcMatches": 1, "beatMatches": 5, "loopMatches": 2, "patternMatches": 0, "storymakersMatch": false, "scoreAvailable": false, "reviewAvailable": false, "activistThesisAvailable": false, "pitchdeckMetadataAvailable": false, "pitchdeckProfileAvailable": false }, "blocks": [], "matches": { "arcs": [ { "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "matchId": "23648562-5ae5-40b6-ada5-5b9b4f4749a3", "evidence": "The deck follows a structure similar to the Sequoia Pitch, with sections on problem, solution, market sizing, traction, and team.", "isPrimary": true, "confidence": 0.9, "extraction": { "at": "2026-07-16 22:43:26.284922+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "beats": [ { "to": 11, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 11, "name": "Problem", "beatId": "0adde54f-802c-40f0-abcd-b53c30e2638d", "matchId": "23648562-5ae5-40b6-ada5-5b9b4f4749a3", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "Slide 11 presents the problem statement: 'Bladder Cancer is a Significant Unmet Medical Need Well Positioned for Innovation and Disruption'.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.9 }, { "to": 10, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 7, "name": "Solution", "beatId": "1146c958-c0a9-4157-948d-c4acb745bb2f", "matchId": "23648562-5ae5-40b6-ada5-5b9b4f4749a3", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "Slides 7-10 present the solution: 'Cretostimogene Grenadenorepvec Selectively Targets Rb-Pathway Defective Cancers' and its mechanism of action.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.9 }, { "to": 12, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 12, "name": "Market Size", "beatId": "50c2fbcb-05ac-4d58-a744-24fa6678ee39", "matchId": "23648562-5ae5-40b6-ada5-5b9b4f4749a3", "beatType": { "name": "Market Size", "slug": "sequoia-pitch-market-size", "status": "active", "canonId": "019dd9b8-20e6-729c-bc28-05442906d032", "version": 1, "description": null }, "evidence": "Slide 12 presents the market sizing: 'NMIBC Represents a Multi-Billion Dollar Market Opportunity in Bladder Cancer'.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.9 }, { "to": 19, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 18, "name": "Traction", "beatId": "d913ba4c-a659-4d05-87f0-7e206fb35199", "matchId": "23648562-5ae5-40b6-ada5-5b9b4f4749a3", "beatType": null, "evidence": "Slides 18-19 present traction: 'First Results From BOND-003: 75.7% CR at Any Time' and 'SUO 2023: First Results from BOND-003'.", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.9 }, { "to": 4, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 4, "name": "Team", "beatId": "775c68ee-ea8d-4dc0-a2ea-df826647911b", "matchId": "23648562-5ae5-40b6-ada5-5b9b4f4749a3", "beatType": { "name": "Team", "slug": "sequoia-pitch-team", "status": "active", "canonId": "019dd9b8-23c9-746f-aaf9-2f5d83892cf3", "version": 1, "description": null }, "evidence": "Slide 4 presents the team: 'The CG Oncology Team'.", "position": 4, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.9 } ], "loops": [ { "to": 40, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null, "categoryName": "Urgency", "categorySlug": "urgency" }, "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed", "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').", "position": 0, "objective": "What are the consequences of not adopting Cretostimogene?", "confidence": 0.8, "extraction": { "at": "2026-07-16 22:43:26.509211+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 15, "from": 13, "loop": { "name": "53_jobs_to_be_done", "slug": "53-jobs-to-be-done", "status": "active", "bestFor": "Product innovation, market entry, competitive positioning", "canonId": "019dd956-7b6c-7594-b5b3-eecbe0ab48e8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying", "familyLabel": null, "categoryName": "Consulting Framework", "categorySlug": "consulting-framework" }, "matchId": "6f9edf1b-df40-4ee7-a622-285d4d2d2fff", "evidence": "The loop is opened on slide 13 ('The Patient Journey') and closed on slide 15 ('Focused Execution Towards Becoming the Leader in High-Risk and Intermediate-Risk Markets').", "position": 1, "objective": "What are the needs of patients with bladder cancer?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:43:26.546084+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "tools": [ { "tool": { "name": "Slide recipe: Cover", "slug": "cover-slide", "status": "active", "bestFor": null, "canonId": "019df269-2a08-767d-9128-e7431e6fe8a3", "version": 1, "bodyDocId": "019df269-29e5-7738-b5fa-6892e5dc8e65", "description": "The first ten seconds. Build it deliberately.", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "3d9286c5-b378-4fdc-a280-7a6ceb4bfc51", "evidence": "CG Oncology", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:44:53.97078+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 1, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "abf63400-3713-4847-a938-ff205d46abfe", "evidence": "CG Oncology Investment Highlights", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:44:54.17833+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Before-After-Bridge", "slug": "before-after-bridge", "status": "active", "bestFor": null, "canonId": "019dd956-8604-7188-883f-42370288ad05", "version": 1, "bodyDocId": null, "description": "Narrative structure: Paint the before, show the after, explain the bridge", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "91ca45dd-879e-4759-97d0-8e5fd977d562", "evidence": "image/illustration: Side-by-side biological illustration of GAG layer interaction with and without DDM surfactant.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 03:58:45.505054+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Problem Statement Canvas", "slug": "problem-statement-canvas", "status": "active", "bestFor": null, "canonId": "019dd956-839d-744b-ad11-9bf3e3642a18", "version": 1, "bodyDocId": null, "description": "Structured definition of the problem: What? Who? Where? When? Scale?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "bb3d85d1-58e6-40af-8c31-e549a0babfc3", "evidence": "Bladder Cancer is a Significant Unmet Medical Need Well Positioned for Innovation and Disruption", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 03:58:45.630223+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 11, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Market Segmentation Pyramid", "slug": "market-segmentation-pyramid", "status": "active", "bestFor": null, "canonId": "1c9f3543-c96f-4a5b-b4a4-9b2a412c0aaf", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "529f4550-deaf-41f9-866c-abf8482ed61a", "evidence": "Hierarchical market segmentation of bladder cancer patients into risk categories and treatment cohorts.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 03:40:19.108545+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Customer journey map", "slug": "customer-journey-map", "status": "active", "bestFor": null, "canonId": "019de52d-1b26-7499-98c8-1091acc836be", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "8590fea5-c529-4700-8872-100cd227f224", "evidence": "The Patient Journey", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 03:40:19.18496+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Process flow", "slug": "process-flow", "status": "active", "bestFor": null, "canonId": "019dd9e1-4dca-76bc-8135-401836a1c4c0", "version": 1, "bodyDocId": null, "description": "Workflow, steps, sequential diagram.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "962056b5-4bd7-465b-9bba-87dbb35f92d3", "evidence": "diagram/process: Ongoing Treatment: Require surveillance and/or treatment every 3 to 6 months for 2 to 5 years", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 03:40:19.222823+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Problem-Agitate-Solve (PAS)", "slug": "problem-agitate-solve-pas", "status": "active", "bestFor": null, "canonId": "019dd956-869f-7564-8d42-de54ed29ab90", "version": 1, "bodyDocId": null, "description": "Identify problem, agitate the pain, present the solution", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "5a38801c-9906-4a5a-ad99-fbd4e5abc5bd", "evidence": "Patient aversion to radical cystectomy associated with significant change in daily routine, surgery-related complications, and mortality rate drives regulatory and sponsor development.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 03:40:19.297165+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 14, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "2x2 matrix", "slug": "matrix-2x2", "status": "active", "bestFor": null, "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8", "version": 1, "bodyDocId": null, "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "7b0ef273-611f-4585-9292-7b4fcc6e804e", "evidence": "Hierarchical market segmentation of bladder cancer patients into risk categories and treatment cohorts.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 03:40:19.371879+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 15, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "SCQA Framework", "slug": "scqa-framework", "status": "active", "bestFor": null, "canonId": "019dd956-7bcb-763f-bdf6-1dfedf3bd36c", "version": 1, "bodyDocId": "019df22a-a0b0-719e-937e-2ac31e53d32c", "description": "Situation, Complication, Question, Answer - structured problem framing", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "8bbd85c1-45ac-43da-9f1c-bd45fefc3b2b", "evidence": "Population: Pathologically confirmed high-risk NMIBC BCG-unresponsive CIS or Ta/T1; Have all Ta/T1 disease resected prior to treatment; Trial designed to be compliant with 2018 FDA guidance", "pageRefs": null, "priority": "Core", "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 03:40:19.448437+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 16, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "2x2 matrix", "slug": "matrix-2x2", "status": "active", "bestFor": null, "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8", "version": 1, "bodyDocId": null, "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "0fbd748f-b3ab-4b26-9b87-c1c888607ef5", "evidence": "table/data: Comparison table of BOND-003, NCT02773849, and KEYNOTE-057 across 9 clinical metrics.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:45:05.707961+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 21, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Comparison frame", "slug": "comparison-frame", "status": "active", "bestFor": null, "canonId": "019dd9e1-484b-7399-a4fc-d14644b99f93", "version": 1, "bodyDocId": null, "description": "Two or more states/subjects placed side by side to expose a gap.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "3987f196-a704-4713-9d90-69822f3c7a19", "evidence": "table/data: Comparison table of BOND-003, NCT02773849, and KEYNOTE-057 across 9 clinical metrics.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:45:05.739383+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 21, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "3c641830-5977-42f0-8bd6-882a09727079", "evidence": "list/bullet: Population: Pathologically confirmed high-risk NMIBC BCG-unresponsive CIS with or without Ta/T1; Have all Ta/T1 disease resected prior to treatment; Trial designed and compliant with 2018 FDA guidance", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:45:05.802836+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 22, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "status": "active", "bestFor": null, "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae", "version": 1, "bodyDocId": null, "description": "Choosing the right chart type for your data and message", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "e56dd2aa-ccd4-4678-9a00-85b612ba29c7", "evidence": "chart/bar-horizontal: Swimmer plot of patient response duration", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:45:05.865492+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 23, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "ade3ca9f-385e-47f6-acad-dd3103e1533b", "evidence": "table/data: Table showing adverse events by grade and frequency", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:45:05.93136+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 24, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "2x2 matrix", "slug": "matrix-2x2", "status": "active", "bestFor": null, "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8", "version": 1, "bodyDocId": null, "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "fb19ec5d-ee1d-4501-8f54-a9c4026f47fd", "evidence": "table/data: Comparison table of 8 clinical trials across 10 metrics including Trial, Intervention, Mechanism, RoA, Stage, Sample Size, BCG-Free Regimen, CR Any Time, CR 6 Mo, CR 12 Mo, and Safety Profile.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:45:05.999788+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 25, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Comparison frame", "slug": "comparison-frame", "status": "active", "bestFor": null, "canonId": "019dd9e1-484b-7399-a4fc-d14644b99f93", "version": 1, "bodyDocId": null, "description": "Two or more states/subjects placed side by side to expose a gap.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "1cdea73f-d8fd-43f0-be69-ebad89af9a0a", "evidence": "table/data: Comparison table of 8 clinical trials across 10 metrics including Trial, Intervention, Mechanism, RoA, Stage, Sample Size, BCG-Free Regimen, CR Any Time, CR 6 Mo, CR 12 Mo, and Safety Profile.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:45:06.037438+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 25, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "c9110b64-e1ad-47c1-9519-59c8e7c348dc", "evidence": "list/bullet: Population: Pathologically confirmed Intermediate-Risk NMIBC (Recurrent LG Ta < 12mo, Solitary LG Ta > 3cm, LG Ta multifocal, HG Ta <= 3cm, LG T1), All disease removed by TURBT at baseline", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:45:06.102279+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 26, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "9298744e-81d1-420a-ac82-c4c1426e5261", "evidence": "list/bullet: Pathologically confirmed high-risk NMIBC; BCG-exposed patients must have had prior BCG therapy; Have all Ta/T1 disease resected prior to treatment", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:45:06.164789+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 27, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "status": "active", "bestFor": null, "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae", "version": 1, "bodyDocId": null, "description": "Choosing the right chart type for your data and message", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "40380a79-e666-450f-a401-85ba5066ec9e", "evidence": "chart/bar-vertical: Clinical trial program mapping to patient segments", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:45:06.229745+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 28, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "39792482-da04-4263-a895-b4eca7f34fd5", "evidence": "list/bullet: Current manufacturing scale supports commercial demand for our lead indication in BCG-unresponsive NMIBC", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:45:06.291359+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 29, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Action Titles", "slug": "action-titles", "status": "active", "bestFor": "Any decision-grade deliverable — strategy recommendation, board update, investment memo, M&A review, post-mortem — where the reader is being asked to agree, decide, or act and will skim the title bar at speed.", "canonId": "019dd956-ac70-700b-a608-ba58e78f5dcc", "version": 1, "bodyDocId": "816dad3c-9983-41c1-a86e-978ebd582841", "description": "The McKinsey-bred discipline of writing every slide title as a complete declarative sentence with a verb and an insight, not a topic label. Each title is a sub-claim that ladders up to the deck's governing thought; read in sequence, the titles reconstruct the executive summary.", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "c01f1d3a-ee4b-4e3c-bbfa-acf6c406bf76", "evidence": "title/action-title: Transformational Expertise in Biologics & Vaccines Manufacturing, Process Development, and Analytical Development", "pageRefs": null, "priority": "Core", "whenToUse": "Any decision-grade deliverable — strategy recommendation, board update, investment memo, M&A review, post-mortem — where the reader is being asked to agree, decide, or act and will skim the title bar at speed.", "confidence": 0.9, "extraction": { "at": "2026-07-17 00:45:06.354986+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 30, "whyItWorks": "Solves two failure modes at once. (1) The buried claim: action titles place the conclusion on the page before any analysis is read, so a busy reader doesn't reverse-engineer it from the chart. (2) The spineless deck: because each title is a claim, slides have to ladder up to the governing thought; logical gaps become visible as topic-shaped titles in a sequence that no longer reads as a story.", "antipattern": "Topic labels disguised as titles — Volume by quarter, Key findings, Pricing strategy, Margins have been impacted. No verb, or a passive verb with no agent, or a fact (Revenue grew 12%) without the so-what. Also: titles that overreach the chart's evidence, multi-claim X-grew-but-Y-fell welded titles, and mechanical repetition of the same X-drove-Y template across the deck.", "cardinality": null, "narrativePurpose": "Forces the deck to carry its argument in the title bar so a senior reader can extract the recommendation without opening a single slide; converts a binder of topics into a navigable pyramid where every slide is a node defending the apex." }, { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "4c9af711-db2e-460f-a111-bc35b3610d7a", "evidence": "list/numbered: 1. Prepare the market\n2. Drive sustainable product differentiation\n3. Establish optimal access and broad reimbursement\n4. Ensure unique and positive customer experience\n5. Launch when fully ready", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:45:06.418963+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 31, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "c23a572e-f66b-4d85-8a08-8c9b07ff8303", "evidence": "list/bullet: Potential backbone oncolytic immunotherapy", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:44:58.0917+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 34, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Slide recipe: Cover", "slug": "cover-slide", "status": "active", "bestFor": null, "canonId": "019df269-2a08-767d-9128-e7431e6fe8a3", "version": 1, "bodyDocId": "019df269-29e5-7738-b5fa-6892e5dc8e65", "description": "The first ten seconds. Build it deliberately.", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "e14956cd-4ee4-4a3b-98c2-02338e6aabee", "evidence": "CG Oncology Inc. 400 Spectrum Center Dr Suite #2040 Irvine, CA 92618", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:44:58.159907+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 35, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "5cf13ccf-1d1d-457e-9d04-03c4dee3d0d2", "evidence": "Regulatory Exclusivity table showing U.S., Europe, Japan, and China exclusivity periods", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:44:58.262519+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 37, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "0512c880-f250-496f-a68a-b8787451a199", "evidence": "Table of adverse events by grade (1, 2, 3, All Grades)", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:44:58.537907+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 44, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "328ac865-deb6-4175-ae7e-0ebfc05c7c0d", "evidence": "The slide is titled 'CG Oncology is Meaningfully Positioned to Become the Leading Company in Bladder Cancer' and includes a section titled 'At a Glance'.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:44:59.288823+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 45, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "336030ab-d564-4ced-8cb4-f5aab08772d6", "evidence": "Circular flow diagram illustrating medical administration steps", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:02:44.193+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "frameworkName": "process" }, { "matchId": "c3fa87a7-986f-4a4a-8833-1f6223ff39ac", "evidence": "Side-by-side comparison of state without and with the surfactant.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:02:44.193+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "frameworkName": "before-after-framing" }, { "matchId": "b36a6992-4248-4ec6-8ed1-a3b74f48ece9", "evidence": "The slide depicts a sequential biological process flow.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:02:45.576+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "frameworkName": "process" }, { "matchId": "ed0a2831-08d3-4140-b7d7-31108ac0d86c", "evidence": "Structured as a three-part breakdown of the clinical and market problem.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:02:49.966+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 11, "frameworkName": "problem-statement" }, { "matchId": "b2b9c9d5-ae50-41b0-9a96-20c65d2f1c50", "evidence": "Visual flow from symptoms to treatment stages", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:02:45.755+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "frameworkName": "customer-journey-map" }, { "matchId": "6922c8a3-4581-40e4-abe2-73873e2217e3", "evidence": "Hierarchical breakdown of total market into risk-based segments.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:02:45.11+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 15, "frameworkName": "market-segmentation-pyramid" }, { "matchId": "8281fd63-56f3-4383-b264-f3515a9cf41b", "evidence": "Direct side-by-side comparison of clinical trial metrics against competitors.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:02:45.755+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 21, "frameworkName": "comparison_frame" }, { "matchId": "7899a50d-8cfe-4568-96f5-c92a849ab5c4", "evidence": "The slide uses a three-stage horizontal flow to describe the clinical trial structure.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:02:46.531+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 22, "frameworkName": "process" }, { "matchId": "f0306a34-642c-41e7-9852-063bdce1e551", "evidence": "The swimmer plot is a variation of a Gantt chart used in clinical trials to show patient duration.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:02:44.83+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 23, "frameworkName": "gantt-chart" }, { "matchId": "6124051b-033a-46a7-ae64-2a7fb05cceba", "evidence": "The slide is structured as a comparative matrix of clinical trial data across multiple competitors.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:02:46.649+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 25, "frameworkName": "comparison_table" }, { "matchId": "b0a6e002-fccd-4acc-9cb7-950b6ab17143", "evidence": "The slide uses a three-column process flow to define the clinical trial methodology.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:02:47.181+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 27, "frameworkName": "process" }, { "matchId": "6366e858-9526-4932-811c-df6bd1a73b25", "evidence": "Hierarchical breakdown of bladder cancer patients by risk and treatment status.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:02:47.326+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 28, "frameworkName": "market-segmentation-pyramid" }, { "matchId": "d1207622-4092-42a3-8986-f6c2ac792c40", "evidence": "Sequential numbered steps for commercialization", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:02:46.877+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 31, "frameworkName": "process" }, { "matchId": "b36b35da-4b9f-461d-86a7-aba7da604194", "evidence": "The visual arrangement of roles around a central customer entity.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:02:47.4+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 32, "frameworkName": "hub-spoke" }, { "matchId": "3927f3ba-8e87-4cb8-8344-0b66a6bf3c75", "evidence": "The slide uses a grid to map project milestones over time.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:02:47.335+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 33, "frameworkName": "gantt-chart" }, { "matchId": "4692e9b8-1d62-4ed5-b539-a9331f15d0e4", "evidence": "The slide uses a multi-dimensional grid to categorize disease risk levels.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:02:52.921+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 39, "frameworkName": "matrix-nxn" }, { "matchId": "ee68c4f0-1c5a-41d2-955a-2f2c1b6aed57", "evidence": "Hierarchical flow chart categorizing patient states based on sequential criteria.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:02:48.432+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 41, "frameworkName": "decision-tree" }, { "matchId": "e8258989-ebb6-45b9-bf35-ecc46ee5330a", "evidence": "Structured data comparison across three clinical trials.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:02:49.944+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 43, "frameworkName": "comparison_table" } ], "patterns": [] }, "storymakers": null, "score": null, "review": null, "activistThesis": null, "pitchdeck": { "metadata": null, "profile": null }, "slides": [ { "page": 1, "type": "setup", "function": "front_matter", "imagePath": "https://imgproxy.kitesheet.com/vrB3ZxvyDUSvCpKrQHdE-g6GaikpH6KjYCeVbeCu-5E/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9jMDJhMWQxY2I3NTU3YmM0MzBjYzhkYzYxY2QyNzA5Ny9wMDAxLmpwZw", "rawType": "cover", "block": null, "metadata": { "slideType": "cover", "slideTypeCanon": { "name": "Cover", "slug": "cover", "status": "active", "canonId": "019de52d-05f2-729d-9f93-e0504f0a2410", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "sparse", "densityScore": 13, "componentCount": 3, "textChars": 89, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:41.948+00", "seconds": 2.261, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/1", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-1", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.35, "x": 0.07, "y": 0.4 }, "kind": "image", "text": "CG Oncology logo", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:41.948+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a7238b3f-6e2f-40d4-9b83-7fe636822756", "parentComponentId": null }, { "bbox": { "h": 1, "w": 0.55, "x": 0.45, "y": 0 }, "kind": "image", "text": "Patient and caregiver photo", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:41.948+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "90d99d7c-9463-4870-b901-3a904aadd0c9", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.25, "x": 0.07, "y": 0.68 }, "kind": "title", "text": "Attacking Bladder Cancer for a Better Tomorrow", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:41.948+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "43402d97-38a3-473d-ad30-eb8d43d5e746", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Slide recipe: Cover", "slug": "cover-slide", "status": "active", "bestFor": null, "canonId": "019df269-2a08-767d-9128-e7431e6fe8a3", "version": 1, "bodyDocId": "019df269-29e5-7738-b5fa-6892e5dc8e65", "description": "The first ten seconds. Build it deliberately.", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "3d9286c5-b378-4fdc-a280-7a6ceb4bfc51", "evidence": "CG Oncology", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:44:53.97078+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 1, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "thumbSrc": "https://imgproxy.kitesheet.com/Njzvcc_WDdKmIEZUXrER-qoT78UmVF9J1USknNEkh8U/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9jMDJhMWQxY2I3NTU3YmM0MzBjYzhkYzYxY2QyNzA5Ny9wMDAxLmpwZw", "imagePathAlt": "https://imgproxy.kitesheet.com/xTtbRSQx77lhpdUblx_j-1IHooArGHaRxSnAVBdkrLw/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9jMDJhMWQxY2I3NTU3YmM0MzBjYzhkYzYxY2QyNzA5Ny9wMDAxLnBuZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/FfEwaZf72B7zXolORul7xOumBq6wb2BxfJCAxSX7zJU/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9jMDJhMWQxY2I3NTU3YmM0MzBjYzhkYzYxY2QyNzA5Ny9wMDAxLnBuZw" }, { "page": 2, "type": "setup", "function": "other", "rawType": "appendix_disclosure", "block": null, "metadata": { "slideType": "appendix_disclosure", "slideTypeCanon": { "name": "Appendix disclosure", "slug": "appendix_disclosure", "status": "active", "canonId": "019de52d-07b2-7549-8e8b-932a19f6e616", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "balanced", "densityScore": 42, "componentCount": 2, "textChars": 4519, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:44.703+00", "seconds": 5, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/2", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-2", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.75, "w": 0.9, "x": 0.05, "y": 0.15 }, "kind": "disclaimer", "text": "This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation including statements regarding our future results of operations and financial position, business strategy, research and development plans, the anticipated timing, costs, design and conduct of our ongoing and planned clinical trials and preclinical studies for cretostimogene and any future product candidates, the timing and likelihood of regulatory filings and approvals for cretostimogene and any future product candidates, our ability to commercialize cretostimogene and any future product candidates, if approved, the pricing and reimbursement of cretostimogene and any future product candidates, if approved, the expected markets and market opportunity for cretostimogene, the timing and likelihood of success, plans and objectives of management for future operations, and future results of anticipated product development efforts, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as \"may,\" \"will,\" \"should,\" \"expect,\" \"plan,\" \"anticipate,\" \"could,\" \"intend,\" \"target,\" \"project,\" \"contemplates,\" \"believes,\" \"estimates,\" \"predicts,\" \"potential\" or \"continue\" or the negative of these terms or other similar expressions.\n\nBecause forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.\n\nTrade names, trademarks and service marks of other companies appearing in this presentation are the property of their respective owners. Solely for convenience, the trademarks and trade names referred to in this presentation appear without the ® and ™ symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the rights of the applicable licensor to these trademarks and tradenames.\n\nThis presentation concerns products that are under clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug Administration. It is currently limited by federal law to investigational use, and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated.\n\nWe have filed a registration statement on Form S-1 (including a preliminary prospectus) with the SEC for the offering to which this presentation relates. Before you invest, you should read the preliminary prospectus in that registration statement and other documents we have filed with the SEC for more complete information about CG Oncology, Inc. and this offering. You may get these documents for free by visiting the SEC website at http://www.sec.gov. Alternatively, copies of the preliminary prospectus may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014 or by email at prospectus@morganstanley.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at Prospectus-ny@ny.email.gs.com; or Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, New York, NY 10022, or by email at prospectus@cantor.com.\n\nThis presentation shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:44.703+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bdb514f6-5461-4ee9-9754-72d3da91ef6e", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.45, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Disclaimer and Forward-Looking Statements", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:44.703+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "63b6d4fe-ee2e-4163-905c-9629b43d2cb6", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 3, "type": "setup", "title": "This is a standard IPO 'deal terms' slide.", "function": "other", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "balanced", "densityScore": 25, "componentCount": 2, "textChars": 258, "nDataPoints": 6, "notes": "This is a standard IPO 'deal terms' slide.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:42.102+00", "seconds": 2.09, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/3", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-3", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.75, "w": 0.96, "x": 0.02, "y": 0.14 }, "kind": "table", "text": "Issuer: CG Oncology, Inc.; Ticker / Exchange: CGON (Nasdaq); Security: Common Stock; Base Offering Size: 11,800,000 shares; Price Range: $16.00 - $18.00; Over-allotment: 15%; Lock-up: 180 days; Bookrunners: Morgan Stanley, Goldman Sachs, Cantor", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:42.102+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6fa4b5ec-1420-47cc-9782-1647531da465", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.2, "x": 0.02, "y": 0.04 }, "kind": "title", "text": "Offering Slide", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:42.102+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d9756bfd-3ecc-4d74-989e-d68a19f3350f", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 4, "type": "setup", "title": "The slide uses a grid layout for five executive profiles, each including a headshot, title, brief bio, and relevant company logos.", "function": "other", "rawType": "team_bio", "block": null, "metadata": { "slideType": "team_bio", "slideTypeCanon": { "name": "Team bio", "slug": "team_bio", "status": "active", "canonId": "019de52d-0a7d-7394-ae5b-037478e71f1e", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "dense", "densityScore": 54, "componentCount": 8, "textChars": 195, "nDataPoints": 0, "notes": "The slide uses a grid layout for five executive profiles, each including a headshot, title, brief bio, and relevant company logos.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:43.962+00", "seconds": 3.95, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/4", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-4", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.18, "w": 0.15, "x": 0.57, "y": 0.5 }, "kind": "image", "text": "Swapnil Bhargava", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:43.962+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "64a85ac0-3c96-473d-a9bd-565ecdffff1d", "parentComponentId": null }, { "bbox": { "h": 0.18, "w": 0.15, "x": 0.83, "y": 0.08 }, "kind": "image", "text": "Vijay Kasturi", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:43.962+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8784f98b-3c2f-4534-a26f-30ac39a9ce5c", "parentComponentId": null }, { "bbox": { "h": 0.18, "w": 0.15, "x": 0.75, "y": 0.5 }, "kind": "image", "text": "Corleen Roche", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:43.962+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a814ad37-f449-41e3-9c58-13ac1003f968", "parentComponentId": null }, { "bbox": { "h": 0.18, "w": 0.15, "x": 0.66, "y": 0.08 }, "kind": "image", "text": "Ambaw Bellete", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:43.962+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c806e414-b804-4927-b627-5e12a01f4524", "parentComponentId": null }, { "bbox": { "h": 0.18, "w": 0.15, "x": 0.48, "y": 0.08 }, "kind": "image", "text": "Arthur Kuan", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:43.962+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f956c0ad-ef15-4b92-954b-8f724348e91f", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.4, "x": 0.03, "y": 0.5 }, "kind": "paragraph", "text": "Deep Industry Experience with Track Record of Success in Oncology Development", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:43.962+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2615bb6c-029f-4ef8-9c09-1404aa9b0a6b", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.4, "x": 0.03, "y": 0.33 }, "kind": "title", "text": "Proven Executive Management Team", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:43.962+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6262b2a1-1253-46c8-9f8a-e607ac063b09", "parentComponentId": null }, { "bbox": { "h": 0.07, "w": 0.35, "x": 0.03, "y": 0.11 }, "kind": "title", "text": "The CG Oncology Team", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:43.962+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "37c25697-b87c-4dd2-bca2-2bcd58b39e2c", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 4, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 4, "name": "Team", "beatId": "775c68ee-ea8d-4dc0-a2ea-df826647911b", "matchId": "23648562-5ae5-40b6-ada5-5b9b4f4749a3", "beatType": { "name": "Team", "slug": "sequoia-pitch-team", "status": "active", "canonId": "019dd9b8-23c9-746f-aaf9-2f5d83892cf3", "version": 1, "description": null }, "evidence": "Slide 4 presents the team: 'The CG Oncology Team'.", "position": 4, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.9 } ], "loops": [], "locked": true }, { "page": 5, "type": "setup", "function": "inspire_vision", "rawType": "mission", "block": null, "metadata": { "slideType": "mission", "slideTypeCanon": { "name": "Mission", "slug": "mission", "status": "active", "canonId": "019de52d-0fce-7496-b34c-18fd6a6e3310", "version": 1, "description": null }, "function": "inspire_vision", "functionCanon": { "name": "Inspire vision", "slug": "inspire_vision", "status": "active", "canonId": "019de52d-16d0-7756-83de-376eeac6fa40", "version": 1, "description": null }, "density": "balanced", "densityScore": 41, "componentCount": 5, "textChars": 290, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:43.458+00", "seconds": 3.371, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/5", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-5", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.3, "w": 0.35, "x": 0.53, "y": 0.34 }, "kind": "image", "text": "CG Oncology logo", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:43.458+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "36b0c4f9-7cd2-4106-83ad-4ff014de1357", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.35, "x": 0.08, "y": 0.62 }, "kind": "paragraph", "text": "We are focused on developing bladder-sparing therapeutics for patients afflicted with bladder cancer.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:43.458+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "029960ba-77ad-4c74-bce4-871c2e8b5e9d", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.35, "x": 0.08, "y": 0.25 }, "kind": "paragraph", "text": "We see a world where urologic cancer patients can benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:43.458+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "53e8ff46-78e1-40c3-863d-74aa92d38c84", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.15, "x": 0.08, "y": 0.54 }, "kind": "title", "text": "Our Mission", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:43.458+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c8601d51-eb3e-408f-994a-2d1adac5329d", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.15, "x": 0.08, "y": 0.165 }, "kind": "title", "text": "Our Vision", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:43.458+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f672d7c4-f3cd-448e-b877-e30575783616", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 6, "type": "setup", "function": "summarize", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "balanced", "densityScore": 38, "componentCount": 3, "textChars": 596, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:47.474+00", "seconds": 7.336, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/6", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-6", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.15, "x": 0.05, "y": 0.45 }, "kind": "image", "text": "CG Oncology logo", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:47.474+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "eab6dd0c-75e9-493b-ac30-48d3936996c5", "parentComponentId": null }, { "bbox": { "h": 0.7, "w": 0.7, "x": 0.25, "y": 0.2 }, "kind": "list", "text": "1. Potential backbone oncolytic immunotherapy targeting a multi-billion dollar market opportunity in lead indication with significant unmet need\n2. Opportunity to expand into additional billion-dollar bladder indications\n3. Demonstrated clinical utility and observed tolerability drives further combination development strategies\n4. Highly concentrated U.S. customer base enables focused execution in sales and marketing for commercialization\n5. Experienced leadership team, seasoned CMC advisory board, and quality Life Sciences-focused investors", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Numbered list", "slug": "numbered", "status": "active", "canonId": "019de52c-fcc0-7718-a284-a4250c805df2", "version": 1, "description": null }, "framework": null }, "subkind": "numbered", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:47.474+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7df4b514-0e85-43fe-9b1a-0328aaf15fa8", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.5, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "CG Oncology Investment Highlights", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:47.474+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ab2205f6-db2b-4a23-9ab8-6f08ead593b2", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "abf63400-3713-4847-a938-ff205d46abfe", "evidence": "CG Oncology Investment Highlights", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:44:54.17833+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 7, "type": "resolution", "title": "Uses a comparative diagram to illustrate the biological mechanism.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 44, "componentCount": 4, "textChars": 522, "nDataPoints": 0, "notes": "Uses a comparative diagram to illustrate the biological mechanism.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:43.249+00", "seconds": 2.843, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/7", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-7", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.38, "w": 0.9, "x": 0.05, "y": 0.22 }, "kind": "image", "text": "Comparative diagram of normal vs tumor cell interaction", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Infographic", "slug": "infographic", "status": "active", "canonId": "019de52c-fe26-750c-9d7d-9f34e21324e8", "version": 1, "description": null }, "framework": null }, "subkind": "infographic", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:43.249+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e9e73b5a-142c-4169-8b90-43709706141b", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.9, "x": 0.05, "y": 0.65 }, "kind": "list", "text": "E2F is a master regulator of gene expression and Cell Cycle Progression. In human cancers, which consistently have retinoblastoma (Rb) pathway-defective cells, Rb cannot bind to E2F. As a result, Cretostimogene grenadenorepvec is designed to replicate.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:43.249+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2872d141-75e1-4585-8254-06082f78e802", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.7, "x": 0.05, "y": 0.95 }, "kind": "source-note", "text": "Laine, et al. Molecular Pathways: Harnessing E2F1 Regulation for Prosenescence Therapy. Molecular Therapy. Vol. 10, No. 4, October 2004.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:43.249+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "88b49bba-b7ff-4d99-a4e1-0a90dcfe9781", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.75, "x": 0.03, "y": 0.05 }, "kind": "title", "text": "Cretostimogene Grenadenorepvec Selectively Targets Rb-Pathway Defective Cancers", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:43.249+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d2111591-deb4-4c5e-bceb-d8080013a2a4", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 10, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 7, "name": "Solution", "beatId": "1146c958-c0a9-4157-948d-c4acb745bb2f", "matchId": "23648562-5ae5-40b6-ada5-5b9b4f4749a3", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "Slides 7-10 present the solution: 'Cretostimogene Grenadenorepvec Selectively Targets Rb-Pathway Defective Cancers' and its mechanism of action.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.9 } ], "loops": [], "locked": true }, { "page": 8, "type": "resolution", "title": "The slide uses a circular process diagram overlaid on a cross-section of a bladder to explain the treatment steps.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 38, "componentCount": 4, "textChars": 376, "nDataPoints": 0, "notes": "The slide uses a circular process diagram overlaid on a cross-section of a bladder to explain the treatment steps.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:44.193+00", "seconds": 3.112, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/8", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-8", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.7, "x": 0.15, "y": 0.15 }, "kind": "diagram", "text": "Circular process flow: Normal Saline Wash -> DDM Wash -> DDM Dwell -> Normal Saline Wash -> Cretostimogene Dwell", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:44.193+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "83c11143-ba75-4ca0-9d71-c1574dde56fd", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.5, "x": 0.25, "y": 0.3 }, "kind": "image", "text": "Cross-section of a bladder showing GAG layer, tumor, catheter, and drug administration", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:44.193+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7362d160-41bd-4b76-ab0c-2dc8efb0c89b", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.2, "x": 0.05, "y": 0.95 }, "kind": "source-note", "text": "1 BCG = Bacillus Calmette Guerin.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:44.193+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2d9172ab-39a5-4579-9069-0aa00ff7436f", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Cretostimogene is Intravesically Administered into the Bladder, Similar to Standard-of-Care BCG Therapy Which Urology Practices Perform Regularly", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:44.193+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3bcad9d5-7534-49cc-99ba-3e849b053982", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "336030ab-d564-4ced-8cb4-f5aab08772d6", "evidence": "Circular flow diagram illustrating medical administration steps", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:02:44.193+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "frameworkName": "process" } ], "arcBeats": [ { "to": 10, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 7, "name": "Solution", "beatId": "1146c958-c0a9-4157-948d-c4acb745bb2f", "matchId": "23648562-5ae5-40b6-ada5-5b9b4f4749a3", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "Slides 7-10 present the solution: 'Cretostimogene Grenadenorepvec Selectively Targets Rb-Pathway Defective Cancers' and its mechanism of action.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.9 } ], "loops": [], "locked": true }, { "page": 9, "type": "resolution", "title": "Uses a before-after framing to explain the mechanism of action for the DDM surfactant.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 52, "componentCount": 6, "textChars": 349, "nDataPoints": 0, "notes": "Uses a before-after framing to explain the mechanism of action for the DDM surfactant.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:44.193+00", "seconds": 2.73, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/9", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-9", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.85, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "image", "text": "Side-by-side biological illustration of GAG layer interaction with and without DDM surfactant.", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:44.193+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b9618b28-800e-4b14-87ab-0abb7fda31eb", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.35, "x": 0.15, "y": 0.15 }, "kind": "paragraph", "text": "The GAG² Layer impedes the binding of the viral vector to the cognate cell receptor.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:44.193+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "18cd47f7-afce-49c0-bf7a-ef0c2560efe1", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.35, "x": 0.6, "y": 0.15 }, "kind": "paragraph", "text": "DDM, a mild detergent, removes the GAG Layer allowing viral infection.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:44.193+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e64aece2-2410-4654-a9b3-c2a7e75b35cd", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.2, "x": 0.15, "y": 0.9 }, "kind": "source-note", "text": "¹ DDM = n-Dodecyl-β-D-maltoside. ² GAG = glycosaminoglycan.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:44.193+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "522cc69b-66ff-4b86-9b0e-562dac623dd9", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.3, "x": 0.65, "y": 0.05 }, "kind": "title", "text": "With DDM Surfactant", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:44.193+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "215829a1-c352-4d8f-8df8-e37c1c96cfd3", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.3, "x": 0.2, "y": 0.05 }, "kind": "title", "text": "Without DDM¹ Surfactant", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:44.193+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c9fb4cf3-c381-4ffe-b8ca-763b05d1bdc9", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Before-After-Bridge", "slug": "before-after-bridge", "status": "active", "bestFor": null, "canonId": "019dd956-8604-7188-883f-42370288ad05", "version": 1, "bodyDocId": null, "description": "Narrative structure: Paint the before, show the after, explain the bridge", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "91ca45dd-879e-4759-97d0-8e5fd977d562", "evidence": "image/illustration: Side-by-side biological illustration of GAG layer interaction with and without DDM surfactant.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 03:58:45.505054+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "c3fa87a7-986f-4a4a-8833-1f6223ff39ac", "evidence": "Side-by-side comparison of state without and with the surfactant.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:02:44.193+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "frameworkName": "before-after-framing" } ], "arcBeats": [ { "to": 10, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 7, "name": "Solution", "beatId": "1146c958-c0a9-4157-948d-c4acb745bb2f", "matchId": "23648562-5ae5-40b6-ada5-5b9b4f4749a3", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "Slides 7-10 present the solution: 'Cretostimogene Grenadenorepvec Selectively Targets Rb-Pathway Defective Cancers' and its mechanism of action.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.9 } ], "loops": [], "locked": true }, { "page": 10, "type": "resolution", "title": "The slide uses a biological process flow to explain the therapeutic mechanism.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 55, "componentCount": 7, "textChars": 288, "nDataPoints": 0, "notes": "The slide uses a biological process flow to explain the therapeutic mechanism.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:45.576+00", "seconds": 3.673, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/10", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-10", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.75, "w": 0.9, "x": 0.05, "y": 0.2 }, "kind": "image", "text": "Biological diagram of oncolytic virus mechanism", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.576+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "86764402-06a0-44b2-8485-2750d3012dab", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.1, "x": 0.88, "y": 0.82 }, "kind": "source-note", "text": "Immune cells", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.576+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "10bc632f-b558-4363-b12a-51c4e190dc79", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.15, "x": 0.52, "y": 0.4 }, "kind": "source-note", "text": "Virus spreads to other tumors", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.576+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "552f0738-ee4c-407f-89ca-b54dddc5e24d", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.1, "x": 0.24, "y": 0.18 }, "kind": "source-note", "text": "Virus enters cells", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.576+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "92b33927-a24e-464b-9341-0055298e2a8e", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.15, "x": 0.65, "y": 0.82 }, "kind": "source-note", "text": "Cytokines and antigens release", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.576+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a7b0634b-2bbd-4d72-b693-66b24517a6d4", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.15, "x": 0.31, "y": 0.77 }, "kind": "source-note", "text": "Virus replicates and kills cancer cells", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.576+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c6107dda-436a-4680-b2e6-1273d0ce7d2c", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Targeted Dual Mode of Action Designed to Produce Selective Oncolysis To Trigger Potent Anti-Tumor Immune Response", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.576+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "721e90a0-6fe7-431b-a98e-595ea9d951f8", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "b36a6992-4248-4ec6-8ed1-a3b74f48ece9", "evidence": "The slide depicts a sequential biological process flow.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:02:45.576+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "frameworkName": "process" } ], "arcBeats": [ { "to": 10, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 7, "name": "Solution", "beatId": "1146c958-c0a9-4157-948d-c4acb745bb2f", "matchId": "23648562-5ae5-40b6-ada5-5b9b4f4749a3", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "Slides 7-10 present the solution: 'Cretostimogene Grenadenorepvec Selectively Targets Rb-Pathway Defective Cancers' and its mechanism of action.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.9 } ], "loops": [], "locked": true }, { "page": 11, "type": "tension", "title": "The slide uses a three-column layout to categorize the problem into prevalence, clinical challenges, and patient profile.", "function": "frame_problem", "rawType": "problem_statement", "block": null, "metadata": { "slideType": "problem_statement", "slideTypeCanon": { "name": "Problem statement", "slug": "problem_statement", "status": "active", "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4", "version": 1, "description": null }, "function": "frame_problem", "functionCanon": { "name": "Frame problem", "slug": "frame_problem", "status": "active", "canonId": "019de52d-13db-753e-ad70-e9b2d0dab398", "version": 1, "description": null }, "density": "dense", "densityScore": 62, "componentCount": 9, "textChars": 159, "nDataPoints": 6, "notes": "The slide uses a three-column layout to categorize the problem into prevalence, clinical challenges, and patient profile.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:49.966+00", "seconds": 8.084, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/11", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-11", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.1, "x": 0.35, "y": 0.4 }, "kind": "metric", "text": "~6%", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:49.966+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "62f8f8b3-6102-4ef5-8eb5-f87460f15031", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.1, "x": 0.65, "y": 0.35 }, "kind": "metric", "text": "74%", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:49.966+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "64c072b2-7199-4975-85ba-f8935ed37409", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.2, "x": 0.05, "y": 0.6 }, "kind": "metric", "text": "725,000+", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:49.966+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ab6c6349-ccdc-4e50-a1a8-bd7d99bb1720", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.2, "x": 0.35, "y": 0.6 }, "kind": "metric", "text": "~15%-61%", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:49.966+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b5c41492-5941-4d63-aac9-18c277d3b3be", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.2, "x": 0.05, "y": 0.35 }, "kind": "metric", "text": "82,000+", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:49.966+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c8f65e37-bc29-416e-9c45-9b71a865b31f", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.05, "x": 0.8, "y": 0.35 }, "kind": "metric", "text": "65", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:49.966+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e7773357-2d55-4248-84df-8e3e1bf2f74a", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.05, "x": 0.65, "y": 0.55 }, "kind": "metric", "text": "73", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:49.966+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f378b2bb-5d70-495c-af19-c64a2f63c0f1", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.9, "x": 0.05, "y": 0.92 }, "kind": "source-note", "text": "1 ACS... 9 Abdalla Aly, et al.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:49.966+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "392298ab-99f8-4212-a9c0-ec3a3c61bd39", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Bladder Cancer is a Significant Unmet Medical Need Well Positioned for Innovation and Disruption", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:49.966+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "59144d69-46f0-4e90-b047-53e5f2104f35", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Problem Statement Canvas", "slug": "problem-statement-canvas", "status": "active", "bestFor": null, "canonId": "019dd956-839d-744b-ad11-9bf3e3642a18", "version": 1, "bodyDocId": null, "description": "Structured definition of the problem: What? Who? Where? When? Scale?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "bb3d85d1-58e6-40af-8c31-e549a0babfc3", "evidence": "Bladder Cancer is a Significant Unmet Medical Need Well Positioned for Innovation and Disruption", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 03:58:45.630223+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 11, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "ed0a2831-08d3-4140-b7d7-31108ac0d86c", "evidence": "Structured as a three-part breakdown of the clinical and market problem.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:02:49.966+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 11, "frameworkName": "problem-statement" } ], "arcBeats": [ { "to": 11, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 11, "name": "Problem", "beatId": "0adde54f-802c-40f0-abcd-b53c30e2638d", "matchId": "23648562-5ae5-40b6-ada5-5b9b4f4749a3", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "Slide 11 presents the problem statement: 'Bladder Cancer is a Significant Unmet Medical Need Well Positioned for Innovation and Disruption'.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.9 } ], "loops": [ { "to": 40, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed", "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').", "position": 0, "objective": "What are the consequences of not adopting Cretostimogene?", "confidence": 0.8, "extraction": { "at": "2026-07-16 22:43:26.509211+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 12, "type": "resolution", "title": "The diagram shows the progression of tumor invasion through the bladder wall layers (Lamina Propria, Inner Muscle, Deep Muscle).", "function": "size_opportunity", "rawType": "market_sizing", "block": null, "metadata": { "slideType": "market_sizing", "slideTypeCanon": { "name": "Market sizing", "slug": "market_sizing", "status": "active", "canonId": "019de52d-08c8-756c-8664-733b73a7ee7b", "version": 1, "description": null }, "function": "size_opportunity", "functionCanon": { "name": "Size opportunity", "slug": "size_opportunity", "status": "active", "canonId": "019de52d-147b-7568-8828-a74a27697618", "version": 1, "description": null }, "density": "dense", "densityScore": 50, "componentCount": 5, "textChars": 346, "nDataPoints": 2, "notes": "The diagram shows the progression of tumor invasion through the bladder wall layers (Lamina Propria, Inner Muscle, Deep Muscle).", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:45.556+00", "seconds": 3.674, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/12", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-12", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.9, "w": 0.4, "x": 0.55, "y": 0.05 }, "kind": "diagram", "text": "Bladder wall staging diagram showing CIS, Ta, T1, T2a, T2b, T3, T4", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Value chain", "slug": "value-chain", "status": "active", "canonId": "019de52d-048a-769c-aad6-4abdde7ef317", "version": 1, "description": null }, "framework": null }, "subkind": "value-chain", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.556+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1c2f39d3-8877-4933-8dfa-553a8465c133", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.45, "x": 0.05, "y": 0.4 }, "kind": "metric", "text": "~75% of Newly Diagnosed Bladder Cancer Cases are NMIBC", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.556+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "79be36aa-ecf4-4e9c-9981-8f3aaf25a2e9", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.45, "x": 0.05, "y": 0.65 }, "kind": "metric", "text": "~25% of Newly Diagnosed Bladder Cancer Cases are MIBC", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.556+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a67acabf-e65c-4306-bed8-815086ff2bcf", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.4, "x": 0.05, "y": 0.95 }, "kind": "source-note", "text": "Cancer of the Urinary Bladder - Cancer Stat Facts. SEER. Chang et al 2016. J Urol. 196:1021-1029.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.556+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3cc9e091-6197-4610-b352-0d378948834c", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.45, "x": 0.05, "y": 0.1 }, "kind": "title", "text": "NMIBC Represents a Multi-Billion Dollar Market Opportunity in Bladder Cancer", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.556+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8fa37179-30cf-4d44-9617-9f9a533387eb", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Market Segmentation Pyramid", "slug": "market-segmentation-pyramid", "status": "active", "bestFor": null, "canonId": "1c9f3543-c96f-4a5b-b4a4-9b2a412c0aaf", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "529f4550-deaf-41f9-866c-abf8482ed61a", "evidence": "Hierarchical market segmentation of bladder cancer patients into risk categories and treatment cohorts.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 03:40:19.108545+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 12, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 12, "name": "Market Size", "beatId": "50c2fbcb-05ac-4d58-a744-24fa6678ee39", "matchId": "23648562-5ae5-40b6-ada5-5b9b4f4749a3", "beatType": { "name": "Market Size", "slug": "sequoia-pitch-market-size", "status": "active", "canonId": "019dd9b8-20e6-729c-bc28-05442906d032", "version": 1, "description": null }, "evidence": "Slide 12 presents the market sizing: 'NMIBC Represents a Multi-Billion Dollar Market Opportunity in Bladder Cancer'.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.9 } ], "loops": [ { "to": 40, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed", "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').", "position": 0, "objective": "What are the consequences of not adopting Cretostimogene?", "confidence": 0.8, "extraction": { "at": "2026-07-16 22:43:26.509211+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 13, "type": "setup", "title": "The slide uses a process flow that transitions into a decision tree/matrix based on risk levels.", "function": "present_framework", "rawType": "customer_journey", "block": null, "metadata": { "slideType": "customer_journey", "slideTypeCanon": { "name": "Customer journey", "slug": "customer_journey", "status": "active", "canonId": "019de52d-0966-70ce-afe3-bc7c98ffc8c9", "version": 1, "description": null }, "function": "present_framework", "functionCanon": { "name": "Present framework", "slug": "present_framework", "status": "active", "canonId": "019de52d-1403-7667-9100-d2ac6709f750", "version": 1, "description": null }, "density": "dense", "densityScore": 62, "componentCount": 6, "textChars": 566, "nDataPoints": 0, "notes": "The slide uses a process flow that transitions into a decision tree/matrix based on risk levels.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:45.755+00", "seconds": 3.848, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/13", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-13", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.2, "x": 0.55, "y": 0.25 }, "kind": "diagram", "text": "Ongoing Treatment: Require surveillance and/or treatment every 3 to 6 months for 2 to 5 years", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.755+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "721e5e20-e02d-47c3-95a9-e7db61a1e14d", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.65, "x": 0.28, "y": 0.45 }, "kind": "framework", "text": "NMIBC risk stratification and treatment pathways", "attrs": null, "canon": { "kind": { "name": "Framework", "slug": "framework", "status": "active", "canonId": "019de52c-fa18-77c6-b10a-ccb8277ac0fa", "version": 1, "description": "Named conceptual framework instance." }, "tool": null, "subkind": { "name": "Framework instance", "slug": "instance", "status": "active", "canonId": "019de52d-05a2-72af-be0b-7edc60708a03", "version": 1, "description": null }, "framework": null }, "subkind": "instance", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.755+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0a99ed5c-a1e4-4b10-b75a-d6873511d2e9", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.135, "x": 0.847, "y": 0.027 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.755+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dfae4a50-c07a-475a-aa25-e0f246b196cb", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.25, "x": 0.05, "y": 0.25 }, "kind": "list", "text": "1. Symptoms: Patient presents to primary care and/or urologist with symptoms (hematuria, urinary frequency). 2. Testing: Work-up may include cystoscopy, urine cytology, and imaging (CT scan, MRI). 3. TURBT: TURBT, followed by tumor staging and grading.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Numbered list", "slug": "numbered", "status": "active", "canonId": "019de52c-fcc0-7718-a284-a4250c805df2", "version": 1, "description": null }, "framework": null }, "subkind": "numbered", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.755+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "47d2fbae-e164-45fd-a0cd-f82938fd35bc", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.25, "y": 0.94 }, "kind": "source-note", "text": "1 TURBT = Transurethral Resection of Bladder Tumor. 2 Due to BCG shortage, NCCN guidelines no longer recommend BCG therapy for Intermediate-Risk patients.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.755+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9cfaebce-a2d9-45d5-863e-9661b0e4129d", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.35, "x": 0.06, "y": 0.08 }, "kind": "title", "text": "The Patient Journey", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.755+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8ea7ef19-0845-42cb-936a-b789eafbb9a7", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Customer journey map", "slug": "customer-journey-map", "status": "active", "bestFor": null, "canonId": "019de52d-1b26-7499-98c8-1091acc836be", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "8590fea5-c529-4700-8872-100cd227f224", "evidence": "The Patient Journey", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 03:40:19.18496+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Process flow", "slug": "process-flow", "status": "active", "bestFor": null, "canonId": "019dd9e1-4dca-76bc-8135-401836a1c4c0", "version": 1, "bodyDocId": null, "description": "Workflow, steps, sequential diagram.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "962056b5-4bd7-465b-9bba-87dbb35f92d3", "evidence": "diagram/process: Ongoing Treatment: Require surveillance and/or treatment every 3 to 6 months for 2 to 5 years", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 03:40:19.222823+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "b2b9c9d5-ae50-41b0-9a96-20c65d2f1c50", "evidence": "Visual flow from symptoms to treatment stages", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:02:45.755+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "frameworkName": "customer-journey-map" } ], "arcBeats": [], "loops": [ { "to": 40, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed", "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').", "position": 0, "objective": "What are the consequences of not adopting Cretostimogene?", "confidence": 0.8, "extraction": { "at": "2026-07-16 22:43:26.509211+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 15, "from": 13, "loop": { "name": "53_jobs_to_be_done", "slug": "53-jobs-to-be-done", "status": "active", "bestFor": "Product innovation, market entry, competitive positioning", "canonId": "019dd956-7b6c-7594-b5b3-eecbe0ab48e8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying", "familyLabel": null }, "matchId": "6f9edf1b-df40-4ee7-a622-285d4d2d2fff", "evidence": "The loop is opened on slide 13 ('The Patient Journey') and closed on slide 15 ('Focused Execution Towards Becoming the Leader in High-Risk and Intermediate-Risk Markets').", "position": 1, "objective": "What are the needs of patients with bladder cancer?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:43:26.546084+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 14, "type": "setup", "title": "The slide highlights the regulatory environment as a key driver for development, citing specific FDA definitions and successful approvals.", "function": "argue_timing", "rawType": "why_now", "block": null, "metadata": { "slideType": "why_now", "slideTypeCanon": { "name": "Why now", "slug": "why_now", "status": "active", "canonId": "019de52d-0f2e-718d-b8ad-256dd87582d0", "version": 1, "description": null }, "function": "argue_timing", "functionCanon": { "name": "Argue timing (why now)", "slug": "argue_timing", "status": "active", "canonId": "019de52d-16f8-74de-9ec2-900be07d90dd", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 79, "componentCount": 8, "textChars": 1031, "nDataPoints": 0, "notes": "The slide highlights the regulatory environment as a key driver for development, citing specific FDA definitions and successful approvals.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:45.899+00", "seconds": 3.906, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/14", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-14", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.2, "x": 0.75, "y": 0.25 }, "kind": "callout", "text": "Two Therapeutic Agents Approved for Full Approval Following Issuance of FDA Guidance*", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.899+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2ab9fd8a-59f9-4585-8d9f-8e7009ab6238", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.15, "x": 0.78, "y": 0.45 }, "kind": "image", "text": "MERCK", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.899+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "855455d2-a8a4-44cc-a776-c2164826f274", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.15, "x": 0.78, "y": 0.58 }, "kind": "image", "text": "FERRING PHARMACEUTICALS", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.899+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "affc7eec-5695-4fb7-b1d2-61c3c09efa49", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.65, "x": 0.03, "y": 0.3 }, "kind": "list", "text": "BCG-unresponsive disease defined as either: Persistent or recurrent CIS alone or with recurrent Ta/T1 disease within 12 months of adequate BCG therapy; Recurrent high-grade Ta/T1 disease within 6 months of completion of adequate BCG therapy, or; T1 high-grade disease following a BCG induction course.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.899+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8e0e2fd3-bcfe-4043-917c-1c239c9c89ad", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.94, "x": 0.03, "y": 0.85 }, "kind": "paragraph", "text": "Patient aversion to radical cystectomy associated with significant change in daily routine, surgery-related complications, and mortality rate drives regulatory and sponsor development.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.899+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0394054a-1c03-4e56-b20c-6dc7a1f5a280", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.65, "x": 0.03, "y": 0.6 }, "kind": "paragraph", "text": "Adequate BCG therapy is defined as at least 5 doses of induction course plus at least 2 doses of maintenance therapy, or at least 5 doses of induction plus at least 2 doses of second induction.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.899+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0b22cf24-eec1-4f26-b644-bab881863245", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.65, "x": 0.03, "y": 0.2 }, "kind": "paragraph", "text": "Single-arm trials with complete response rate as primary endpoint in the context of duration of response may be appropriate for a full approval.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.899+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "50ed021b-949b-4c18-b367-2599fd3a4f45", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.94, "x": 0.03, "y": 0.05 }, "kind": "title", "text": "FDA Guidance on BCG-Unresponsive NMIBC De-Risks Development & Regulatory Pathway to BLA Approval", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.899+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4f858841-8524-4529-bd68-7f690d955ec3", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Problem-Agitate-Solve (PAS)", "slug": "problem-agitate-solve-pas", "status": "active", "bestFor": null, "canonId": "019dd956-869f-7564-8d42-de54ed29ab90", "version": 1, "bodyDocId": null, "description": "Identify problem, agitate the pain, present the solution", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "5a38801c-9906-4a5a-ad99-fbd4e5abc5bd", "evidence": "Patient aversion to radical cystectomy associated with significant change in daily routine, surgery-related complications, and mortality rate drives regulatory and sponsor development.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 03:40:19.297165+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 14, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [ { "to": 40, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed", "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').", "position": 0, "objective": "What are the consequences of not adopting Cretostimogene?", "confidence": 0.8, "extraction": { "at": "2026-07-16 22:43:26.509211+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 15, "from": 13, "loop": { "name": "53_jobs_to_be_done", "slug": "53-jobs-to-be-done", "status": "active", "bestFor": "Product innovation, market entry, competitive positioning", "canonId": "019dd956-7b6c-7594-b5b3-eecbe0ab48e8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying", "familyLabel": null }, "matchId": "6f9edf1b-df40-4ee7-a622-285d4d2d2fff", "evidence": "The loop is opened on slide 13 ('The Patient Journey') and closed on slide 15 ('Focused Execution Towards Becoming the Leader in High-Risk and Intermediate-Risk Markets').", "position": 1, "objective": "What are the needs of patients with bladder cancer?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:43:26.546084+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 15, "type": "setup", "title": "The slide uses a hierarchical tree structure to map clinical trials to specific patient segments (Intermediate vs High Risk, BCG-naïve/exposed/unresponsive).", "function": "decompose_segments", "rawType": "segmentation", "block": null, "metadata": { "slideType": "segmentation", "slideTypeCanon": { "name": "Segmentation", "slug": "segmentation", "status": "active", "canonId": "019de52d-0917-75d5-9172-1b3b3c2f6400", "version": 1, "description": null }, "function": "decompose_segments", "functionCanon": { "name": "Decompose segments", "slug": "decompose_segments", "status": "active", "canonId": "019de52d-14f1-74f8-be75-beb0be1135ec", "version": 1, "description": null }, "density": "balanced", "densityScore": 45, "componentCount": 4, "textChars": 373, "nDataPoints": 6, "notes": "The slide uses a hierarchical tree structure to map clinical trials to specific patient segments (Intermediate vs High Risk, BCG-naïve/exposed/unresponsive).", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:45.11+00", "seconds": 3.019, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/15", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-15", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.9, "x": 0.05, "y": 0.15 }, "kind": "diagram", "text": "Hierarchical market segmentation of bladder cancer patients into risk categories and treatment cohorts.", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.11+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7c9dc803-910e-4a94-b089-ed102969fba4", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.3, "x": 0.05, "y": 0.9 }, "kind": "list", "text": "Current Program vs Planned Studies legend", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.11+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c7980f41-85e7-4968-b30c-e50cc764c1d7", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.5, "x": 0.35, "y": 0.9 }, "kind": "paragraph", "text": "* CORE-008 is a multi-cohort planned study to evaluate cretostimogene in BCG-exposed and BCG-naïve NMIBC.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.11+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ef2d0de8-ce98-4fad-87ed-36a2caa17efc", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Focused Execution Towards Becoming the Leader in High-Risk and Intermediate-Risk Markets with Multi-Billion Dollar Potential", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.11+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dbc83559-0833-47ac-84e8-34127e664c26", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "2x2 matrix", "slug": "matrix-2x2", "status": "active", "bestFor": null, "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8", "version": 1, "bodyDocId": null, "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "7b0ef273-611f-4585-9292-7b4fcc6e804e", "evidence": "Hierarchical market segmentation of bladder cancer patients into risk categories and treatment cohorts.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 03:40:19.371879+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 15, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "6922c8a3-4581-40e4-abe2-73873e2217e3", "evidence": "Hierarchical breakdown of total market into risk-based segments.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:02:45.11+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 15, "frameworkName": "market-segmentation-pyramid" } ], "arcBeats": [], "loops": [ { "to": 40, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed", "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').", "position": 0, "objective": "What are the consequences of not adopting Cretostimogene?", "confidence": 0.8, "extraction": { "at": "2026-07-16 22:43:26.509211+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 15, "from": 13, "loop": { "name": "53_jobs_to_be_done", "slug": "53-jobs-to-be-done", "status": "active", "bestFor": "Product innovation, market entry, competitive positioning", "canonId": "019dd956-7b6c-7594-b5b3-eecbe0ab48e8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying", "familyLabel": null }, "matchId": "6f9edf1b-df40-4ee7-a622-285d4d2d2fff", "evidence": "The loop is opened on slide 13 ('The Patient Journey') and closed on slide 15 ('Focused Execution Towards Becoming the Leader in High-Risk and Intermediate-Risk Markets').", "position": 1, "objective": "What are the needs of patients with bladder cancer?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:43:26.546084+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 16, "type": "resolution", "title": "Includes FDA Fast Track and Breakthrough Therapy designations.", "function": "plan_implementation", "rawType": "appendix_methodology", "block": null, "metadata": { "slideType": "appendix_methodology", "slideTypeCanon": { "name": "Appendix methodology", "slug": "appendix_methodology", "status": "active", "canonId": "019de52d-07d9-726c-8599-167f2d2ffaa7", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 80, "componentCount": 7, "textChars": 818, "nDataPoints": 4, "notes": "Includes FDA Fast Track and Breakthrough Therapy designations.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:45.315+00", "seconds": 3.128, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/16", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-16", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.12, "w": 0.92, "x": 0.04, "y": 0.325 }, "kind": "diagram", "text": "BCG-Unresponsive NMIBC | Cretostimogene Single-Arm, Open-Label, IVe Administration | CR at Any Time (CIS) EFS (Ta/T1)", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.315+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9f2fd199-346c-4546-b2bc-1e247fdf72be", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.15, "x": 0.82, "y": 0.02 }, "kind": "image", "text": "FDA Fast Track and Breakthrough Therapy logos", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.315+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "80377eae-5ca9-4ca0-a263-f16ce01217f9", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.3, "x": 0.04, "y": 0.53 }, "kind": "list", "text": "Population: Pathologically confirmed high-risk NMIBC BCG-unresponsive CIS or Ta/T1; Have all Ta/T1 disease resected prior to treatment; Trial designed to be compliant with 2018 FDA guidance", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.315+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1ab05a5c-844b-4afb-a0da-9c9525efe66c", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.2, "x": 0.75, "y": 0.53 }, "kind": "list", "text": "Additional Endpoints: Cohort C (CR at 12 months, DoR, PFS); Cohort P (RFS, PFS)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.315+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "606aea5c-cadd-4082-88d1-46675369cad9", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.3, "x": 0.35, "y": 0.53 }, "kind": "list", "text": "Study Design / Regimen: Cohort C (n=116) induction/maintenance; Cohort P (n=70) induction/maintenance", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.315+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6852f998-35e1-45e3-8b1d-8915d96605d2", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.5, "x": 0.04, "y": 0.94 }, "kind": "source-note", "text": "1Second induction course of weekly x 6 for non-responders at month 3. Note: Patients undergo urine cytology and cystoscopy every 3 months for first 2 years; mandatory, site-directed biopsy at month 12.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.315+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "33e037b6-38a8-4f1b-9aad-f1cc297f8c36", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.88, "x": 0.06, "y": 0.14 }, "kind": "title", "text": "Phase 3 Cretostimogene Monotherapy for High-Risk, BCG-Unresponsive NMIBC (NCT04452591)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.315+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "13a1bd2d-55d1-4cf2-821c-44debf624801", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "SCQA Framework", "slug": "scqa-framework", "status": "active", "bestFor": null, "canonId": "019dd956-7bcb-763f-bdf6-1dfedf3bd36c", "version": 1, "bodyDocId": "019df22a-a0b0-719e-937e-2ac31e53d32c", "description": "Situation, Complication, Question, Answer - structured problem framing", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "8bbd85c1-45ac-43da-9f1c-bd45fefc3b2b", "evidence": "Population: Pathologically confirmed high-risk NMIBC BCG-unresponsive CIS or Ta/T1; Have all Ta/T1 disease resected prior to treatment; Trial designed to be compliant with 2018 FDA guidance", "pageRefs": null, "priority": "Core", "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 03:40:19.448437+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 16, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [ { "to": 40, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed", "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').", "position": 0, "objective": "What are the consequences of not adopting Cretostimogene?", "confidence": 0.8, "extraction": { "at": "2026-07-16 22:43:26.509211+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 17, "type": "analysis", "title": "BOND-003 study data.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "balanced", "densityScore": 46, "componentCount": 4, "textChars": 362, "nDataPoints": 22, "notes": "BOND-003 study data.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:45.084+00", "seconds": 2.755, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/17", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-17", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.03, "w": 0.5, "x": 0.05, "y": 0.95 }, "kind": "disclaimer", "text": "Efficacy data cutoff as of October 5, 2023. ECOG = Eastern Cooperative Oncology Group. TICE = BCG strain manufactured by Merck.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.084+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "60efa574-cd73-4b9c-acad-2303b0d154dc", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.33, "x": 0.63, "y": 0.16 }, "kind": "list", "text": "Majority of patients are male (76%), white (56%), > 65 years (80%). ECOG 0 at baseline (80%). Qualifying BCG: TICE most common (83%).", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.084+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e33a81fc-4478-4d0f-b587-4c2e41b576f0", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.55, "x": 0.07, "y": 0.16 }, "kind": "table", "text": "Gender, Age, ECOG, BCG History, High-Risk NMIBC T-Stage", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.084+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "af606309-48bd-4c7a-9b14-7ee8c667009e", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.18, "y": 0.06 }, "kind": "title", "text": "Patient Demographics & Baseline Characteristics", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.084+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b10d8b3c-c530-4302-b869-a504dd6631ac", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 40, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed", "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').", "position": 0, "objective": "What are the consequences of not adopting Cretostimogene?", "confidence": 0.8, "extraction": { "at": "2026-07-16 22:43:26.509211+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 18, "type": "evidence", "title": "Efficacy data cutoff as of October 5, 2023. Footnote indicates some patients excluded from 6-month assessment.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 54, "componentCount": 5, "textChars": 379, "nDataPoints": 7, "notes": "Efficacy data cutoff as of October 5, 2023. Footnote indicates some patients excluded from 6-month assessment.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:45.393+00", "seconds": 3.083, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/18", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-18", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.55, "w": 0.35, "x": 0.08, "y": 0.35 }, "kind": "chart", "text": "CR rates at any time and lasting >= 6 months", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.393+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7f412388-e959-4665-a07d-b9493b3794b2", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.8, "x": 0.06, "y": 0.95 }, "kind": "disclaimer", "text": "Efficacy data cutoff as of October 5, 2023. Seven patients yet to reach minimum duration of response evaluation and not included in durable CR lasting ≥ 6 months assessment.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.393+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c1052fa7-fb64-4d65-8277-09927592164c", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.55, "x": 0.418, "y": 0.33 }, "kind": "table", "text": "Response Evaluation table showing CR percentages and n/N counts", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.393+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4e7beb02-2d0e-4514-a7f6-b0e6fd7b8b0b", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.6, "x": 0.06, "y": 0.21 }, "kind": "title", "text": "74.4% of Responders Maintained Response ≥ 6 Months", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.393+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f7b9adde-7039-492c-a3e1-f82f73c684d2", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.88, "x": 0.06, "y": 0.14 }, "kind": "title", "text": "First Results From BOND-003: 75.7% CR at Any Time", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.393+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "307ad954-a399-44c2-8e79-3dfafb1df8a1", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 19, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 18, "name": "Traction", "beatId": "d913ba4c-a659-4d05-87f0-7e206fb35199", "matchId": "23648562-5ae5-40b6-ada5-5b9b4f4749a3", "beatType": null, "evidence": "Slides 18-19 present traction: 'First Results From BOND-003: 75.7% CR at Any Time' and 'SUO 2023: First Results from BOND-003'.", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.9 } ], "loops": [ { "to": 40, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed", "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').", "position": 0, "objective": "What are the consequences of not adopting Cretostimogene?", "confidence": 0.8, "extraction": { "at": "2026-07-16 22:43:26.509211+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 19, "type": "evidence", "title": "The slide uses a swimmer plot to visualize individual patient response durations, including complete response, recurrence, and reinduction events.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 71, "componentCount": 6, "textChars": 592, "nDataPoints": 11, "notes": "The slide uses a swimmer plot to visualize individual patient response durations, including complete response, recurrence, and reinduction events.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:45.889+00", "seconds": 3.542, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/19", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-19", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.75, "w": 0.65, "x": 0.03, "y": 0.15 }, "kind": "chart", "text": "Swimmer plot of patient responses over time", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Horizontal bar chart", "slug": "bar-horizontal", "status": "active", "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f", "version": 1, "description": null }, "framework": null }, "subkind": "bar-horizontal", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.889+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "32fecfeb-7ccc-48b6-bdea-2108e91e37f2", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.15, "x": 0.52, "y": 0.76 }, "kind": "legend", "text": "Ongoing Response, Complete Response, Recurrence/Non-Response, Second Induction, Discontinued Study", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.889+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bd339b20-d986-40fc-974a-5ec00a363fe1", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.22, "x": 0.75, "y": 0.15 }, "kind": "list", "text": "Key Highlights from SUO 2023: Of the 50 evaluable responders, 84% maintained their CR for at least 3 months; Of the 43 evaluable responders, 74% maintained their CR for at least 6 months; Of the 13 patients who were subsequently reinduced, 31% were salvaged.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.889+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0fcc98ed-0be7-46f4-b579-f407090fabfd", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.4, "x": 0.55, "y": 0.58 }, "kind": "metric", "text": "CR at Any Time 76% (50/66); CR Rate at 3 Months: 68% (45/66); CR Rate at 6 Months: 64% (42/66)", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.889+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0c659b2e-5727-49e9-b1a9-651e1fe2d888", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.25, "x": 0.7, "y": 0.78 }, "kind": "metric", "text": "Durable CR >= 3 Mo 84% (42/50); Durable CR >= 6 Mo 74% (32/43)", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.889+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c3d9fdfb-b799-43de-a1b0-dc94a27446f0", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.5, "x": 0.18, "y": 0.05 }, "kind": "title", "text": "SUO 2023: First Results from BOND-003", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.889+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a98b80cc-4071-4baf-bcb9-ae09cc320ecc", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 19, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 18, "name": "Traction", "beatId": "d913ba4c-a659-4d05-87f0-7e206fb35199", "matchId": "23648562-5ae5-40b6-ada5-5b9b4f4749a3", "beatType": null, "evidence": "Slides 18-19 present traction: 'First Results From BOND-003: 75.7% CR at Any Time' and 'SUO 2023: First Results from BOND-003'.", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.9 } ], "loops": [ { "to": 40, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed", "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').", "position": 0, "objective": "What are the consequences of not adopting Cretostimogene?", "confidence": 0.8, "extraction": { "at": "2026-07-16 22:43:26.509211+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 20, "type": "analysis", "title": "BOND-003 clinical trial safety data.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 66, "componentCount": 5, "textChars": 671, "nDataPoints": 14, "notes": "BOND-003 clinical trial safety data.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:45.755+00", "seconds": 3.348, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/20", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-20", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.4, "w": 0.4, "x": 0.05, "y": 0.042 }, "kind": "list", "text": "Nearly all AEs were transient Grade 1-2 local urinary tract symptoms; No Grade ≥ 3 treatment-related AEs reported; Two patients (1.8%) had SAEs (Grade 2); No treatment discontinuations due to AEs; No deaths were reported", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.755+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8f1e99f6-edf9-4ee0-aa88-70b4772858b5", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.4, "x": 0.05, "y": 0.95 }, "kind": "source-note", "text": "Safety data cutoff as of September 8, 2023. Treatment-related SAEs were noninfective cystitis (Grade 2) and clot retention (Grade 2).", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.755+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "653e6d12-395e-4e8e-9d42-db004aaf0e4d", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.32 }, "kind": "subtitle", "text": "Top Adverse Events Considered Related to Cretostimogene Administration For All Patients (n=112) By Grade", "attrs": null, "canon": { "kind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "82d821ee-2793-42e7-8f16-c6131385a3ce", "version": 1, "description": "Header-zone supporting text near the title (= ex body.description with bbox)." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.755+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6564db37-d933-4cff-9dce-9a0f94d91d6b", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.5, "x": 0.046, "y": 0.039 }, "kind": "table", "text": "Patients with TRAEs; Any Grade (%); Grade ≥ 3 (%); Bladder Spasm; Pollakiuria; Dysuria; Micturition Urgency; Hematuria", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.755+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a706b463-83bf-40d3-b711-e01c9c6cfe3b", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.15 }, "kind": "title", "text": "Cretostimogene Has Been Generally Well-Tolerated With No Grade 3 Or Higher Treatment-Related AEs", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.755+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8cc3b81d-8b9f-4a08-bee1-5754b72ef184", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 40, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed", "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').", "position": 0, "objective": "What are the consequences of not adopting Cretostimogene?", "confidence": 0.8, "extraction": { "at": "2026-07-16 22:43:26.509211+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 21, "type": "setup", "title": "The slide explicitly notes that these are not head-to-head studies.", "function": "compare_peers", "rawType": "competitive_analysis", "block": null, "metadata": { "slideType": "competitive_analysis", "slideTypeCanon": { "name": "Competitive analysis", "slug": "competitive_analysis", "status": "active", "canonId": "019de52d-093e-776b-94c6-c1573f5f1a31", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "balanced", "densityScore": 40, "componentCount": 3, "textChars": 401, "nDataPoints": 24, "notes": "The slide explicitly notes that these are not head-to-head studies.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:45.755+00", "seconds": 3.187, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/21", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-21", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.88, "x": 0.06, "y": 0.92 }, "kind": "disclaimer", "text": "These data are not based on head-to-head or comparator studies. Differences exist between study designs and subject characteristics, and caution should be exercised when comparing data across studies.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.755+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "aaf17d4d-8989-4f86-8d62-63e22eb36856", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.88, "x": 0.06, "y": 0.2 }, "kind": "table", "text": "Comparison table of BOND-003, NCT02773849, and KEYNOTE-057 across 9 clinical metrics.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.755+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "528a3714-2713-4ba4-80d4-c378919ecd50", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.75, "x": 0.18, "y": 0.05 }, "kind": "title", "text": "Pioneering First-in-Class Oncolytic Immunotherapy with Differentiated Clinical Profile Against Approved NMIBC Agents", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.755+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ad5fe38b-d196-4a2a-981e-c96883951cd8", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "2x2 matrix", "slug": "matrix-2x2", "status": "active", "bestFor": null, "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8", "version": 1, "bodyDocId": null, "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "0fbd748f-b3ab-4b26-9b87-c1c888607ef5", "evidence": "table/data: Comparison table of BOND-003, NCT02773849, and KEYNOTE-057 across 9 clinical metrics.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:45:05.707961+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 21, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Comparison frame", "slug": "comparison-frame", "status": "active", "bestFor": null, "canonId": "019dd9e1-484b-7399-a4fc-d14644b99f93", "version": 1, "bodyDocId": null, "description": "Two or more states/subjects placed side by side to expose a gap.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "3987f196-a704-4713-9d90-69822f3c7a19", "evidence": "table/data: Comparison table of BOND-003, NCT02773849, and KEYNOTE-057 across 9 clinical metrics.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:45:05.739383+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 21, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "8281fd63-56f3-4383-b264-f3515a9cf41b", "evidence": "Direct side-by-side comparison of clinical trial metrics against competitors.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:02:45.755+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 21, "frameworkName": "comparison_frame" } ], "arcBeats": [], "loops": [ { "to": 40, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed", "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').", "position": 0, "objective": "What are the consequences of not adopting Cretostimogene?", "confidence": 0.8, "extraction": { "at": "2026-07-16 22:43:26.509211+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 22, "type": "setup", "title": "The slide uses a process-flow style layout to define the clinical trial parameters.", "function": "present_framework", "rawType": "appendix_methodology", "block": null, "metadata": { "slideType": "appendix_methodology", "slideTypeCanon": { "name": "Appendix methodology", "slug": "appendix_methodology", "status": "active", "canonId": "019de52d-07d9-726c-8599-167f2d2ffaa7", "version": 1, "description": null }, "function": "present_framework", "functionCanon": { "name": "Present framework", "slug": "present_framework", "status": "active", "canonId": "019de52d-1403-7667-9100-d2ac6709f750", "version": 1, "description": null }, "density": "dense", "densityScore": 67, "componentCount": 6, "textChars": 794, "nDataPoints": 0, "notes": "The slide uses a process-flow style layout to define the clinical trial parameters.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:46.531+00", "seconds": 4.024, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/22", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-22", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.3 }, "kind": "diagram", "text": "BCG-Unresponsive NMIBC -> Cretostimogene -> CR at 12-months", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:46.531+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "eec68a2a-cd69-4dee-834e-07feae587cc4", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.35, "x": 0.35, "y": 0.45 }, "kind": "list", "text": "Study Design / Regimen: Creto Induction = Weekly x 6; Second induction course = Weekly x 3 or 6; Maintenance courses = Weekly x 3; Pembrolizumab = Every 6 weeks (400 mg) through Year 2", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:46.531+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a9365da1-6f8a-44d6-b29c-b44093afa52e", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.2, "x": 0.72, "y": 0.45 }, "kind": "list", "text": "Additional Endpoints: CR at Any Time; DoR; PFS; Safety", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:46.531+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bb61ef32-2539-4bc2-943c-56569855f822", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.3, "x": 0.05, "y": 0.45 }, "kind": "list", "text": "Population: Pathologically confirmed high-risk NMIBC BCG-unresponsive CIS with or without Ta/T1; Have all Ta/T1 disease resected prior to treatment; Trial designed and compliant with 2018 FDA guidance", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:46.531+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d6552cdb-b987-4f41-8b60-844d67ae9416", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.5, "x": 0.05, "y": 0.92 }, "kind": "source-note", "text": "Second induction course of weekly x 6 for non-responders at month 3. Maintenance course for complete responders starts at month 3 every 3 months for 1st year, and every 6 months for 2nd year.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:46.531+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9c6e110a-db43-423a-831d-736c72ee2da1", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.9, "x": 0.05, "y": 0.12 }, "kind": "title", "text": "Phase 2 Cretostimogene + Pembrolizumab for High-Risk, BCG-Unresponsive NMIBC, CIS-Containing (NCT04387461)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:46.531+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8dfe3520-727d-47d8-adc9-a88f032a7eda", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "3c641830-5977-42f0-8bd6-882a09727079", "evidence": "list/bullet: Population: Pathologically confirmed high-risk NMIBC BCG-unresponsive CIS with or without Ta/T1; Have all Ta/T1 disease resected prior to treatment; Trial designed and compliant with 2018 FDA guidance", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:45:05.802836+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 22, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "7899a50d-8cfe-4568-96f5-c92a849ab5c4", "evidence": "The slide uses a three-stage horizontal flow to describe the clinical trial structure.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:02:46.531+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 22, "frameworkName": "process" } ], "arcBeats": [], "loops": [ { "to": 40, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed", "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').", "position": 0, "objective": "What are the consequences of not adopting Cretostimogene?", "confidence": 0.8, "extraction": { "at": "2026-07-16 22:43:26.509211+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 23, "type": "evidence", "title": "The slide uses a swimmer plot to visualize patient-level clinical trial data.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "balanced", "densityScore": 25, "componentCount": 3, "textChars": 152, "nDataPoints": 9, "notes": "The slide uses a swimmer plot to visualize patient-level clinical trial data.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:44.83+00", "seconds": 2.161, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/23", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-23", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.85, "x": 0.04, "y": 0.15 }, "kind": "chart", "text": "Swimmer plot of patient response duration", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Horizontal bar chart", "slug": "bar-horizontal", "status": "active", "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f", "version": 1, "description": null }, "framework": null }, "subkind": "bar-horizontal", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:44.83+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4c12f1e5-2689-4642-9a53-3d9c27081dcd", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.5, "x": 0.18, "y": 0.09 }, "kind": "subtitle", "text": "Cretostimogene + Pembrolizumab Combo for BCG-Unresponsive NMIBC", "attrs": null, "canon": { "kind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "82d821ee-2793-42e7-8f16-c6131385a3ce", "version": 1, "description": "Header-zone supporting text near the title (= ex body.description with bbox)." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:44.83+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "80d3b8c2-c8ab-41b7-b33b-bca4a7de9444", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.7, "x": 0.18, "y": 0.03 }, "kind": "title", "text": "AUA 2023: Updated Interim Data in CORE-001 Study", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:44.83+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "63770751-674f-421d-a90f-0ef9af431367", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "status": "active", "bestFor": null, "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae", "version": 1, "bodyDocId": null, "description": "Choosing the right chart type for your data and message", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "e56dd2aa-ccd4-4678-9a00-85b612ba29c7", "evidence": "chart/bar-horizontal: Swimmer plot of patient response duration", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:45:05.865492+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 23, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "f0306a34-642c-41e7-9852-063bdce1e551", "evidence": "The swimmer plot is a variation of a Gantt chart used in clinical trials to show patient duration.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:02:44.83+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 23, "frameworkName": "gantt-chart" } ], "arcBeats": [], "loops": [ { "to": 40, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed", "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').", "position": 0, "objective": "What are the consequences of not adopting Cretostimogene?", "confidence": 0.8, "extraction": { "at": "2026-07-16 22:43:26.509211+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 24, "type": "analysis", "title": "The table lists specific medical conditions (Preferred Terms) and their occurrence rates across 35 patients.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "balanced", "densityScore": 45, "componentCount": 3, "textChars": 485, "nDataPoints": 75, "notes": "The table lists specific medical conditions (Preferred Terms) and their occurrence rates across 35 patients.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:45.471+00", "seconds": 2.26, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/24", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-24", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.9, "x": 0.05, "y": 0.92 }, "kind": "disclaimer", "text": "AUA 2023, Abstract #23-5631 - CORE-001: Phase 2 Single Arm Study of Creto Combined with Pembrolizumab in Patients with Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin (BCG). *Most frequent grade 1-2 AE and all grade 3 or higher AE related to treatment. Safety data cutoff as of January 31, 2023.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.471+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "88043223-336d-45f4-8c92-c0d9733fd11d", "parentComponentId": null }, { "bbox": { "h": 0.75, "w": 0.9, "x": 0.05, "y": 0.15 }, "kind": "table", "text": "Table showing adverse events by grade and frequency", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.471+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4401ce3f-3bd9-4643-9a16-9f489afe72a0", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.75, "x": 0.18, "y": 0.05 }, "kind": "title", "text": "Tolerable Interim Safety Results with Acceptable Immune-Related AE Within Expectations in PD-1 Checkpoint Combo", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:45.471+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ea31dc90-f931-4cf6-bc6a-9fefaac797eb", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "ade3ca9f-385e-47f6-acad-dd3103e1533b", "evidence": "table/data: Table showing adverse events by grade and frequency", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:45:05.93136+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 24, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [ { "to": 40, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed", "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').", "position": 0, "objective": "What are the consequences of not adopting Cretostimogene?", "confidence": 0.8, "extraction": { "at": "2026-07-16 22:43:26.509211+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 25, "type": "setup", "title": "The slide uses a detailed comparison table to highlight the competitive positioning of CG Oncology's CORE-001 trial against other industry players.", "function": "compare_peers", "rawType": "competitive_analysis", "block": null, "metadata": { "slideType": "competitive_analysis", "slideTypeCanon": { "name": "Competitive analysis", "slug": "competitive_analysis", "status": "active", "canonId": "019de52d-093e-776b-94c6-c1573f5f1a31", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "balanced", "densityScore": 43, "componentCount": 3, "textChars": 460, "nDataPoints": 48, "notes": "The slide uses a detailed comparison table to highlight the competitive positioning of CG Oncology's CORE-001 trial against other industry players.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:46.649+00", "seconds": 3.617, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/25", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-25", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.06, "w": 0.96, "x": 0.02, "y": 0.93 }, "kind": "disclaimer", "text": "These data are not based on head-to-head or comparator studies. Differences exist between study designs and subject characteristics...", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:46.649+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5a0edb97-a68c-4cd5-939e-ec1bd5974299", "parentComponentId": null }, { "bbox": { "h": 0.68, "w": 0.96, "x": 0.02, "y": 0.22 }, "kind": "table", "text": "Comparison table of 8 clinical trials across 10 metrics including Trial, Intervention, Mechanism, RoA, Stage, Sample Size, BCG-Free Regimen, CR Any Time, CR 6 Mo, CR 12 Mo, and Safety Profile.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:46.649+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c6726bcd-e7a8-4bed-be18-ca2a70e34674", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.75, "x": 0.21, "y": 0.03 }, "kind": "title", "text": "Pioneering Oncolytic Immunotherapy with Differentiated Clinical Results Compared to Approved and In Development Agents in BCG-UR NMIBC", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:46.649+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2c9cad47-fd41-4a93-bad2-debfbca3e69e", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "2x2 matrix", "slug": "matrix-2x2", "status": "active", "bestFor": null, "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8", "version": 1, "bodyDocId": null, "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "fb19ec5d-ee1d-4501-8f54-a9c4026f47fd", "evidence": "table/data: Comparison table of 8 clinical trials across 10 metrics including Trial, Intervention, Mechanism, RoA, Stage, Sample Size, BCG-Free Regimen, CR Any Time, CR 6 Mo, CR 12 Mo, and Safety Profile.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:45:05.999788+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 25, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Comparison frame", "slug": "comparison-frame", "status": "active", "bestFor": null, "canonId": "019dd9e1-484b-7399-a4fc-d14644b99f93", "version": 1, "bodyDocId": null, "description": "Two or more states/subjects placed side by side to expose a gap.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "1cdea73f-d8fd-43f0-be69-ebad89af9a0a", "evidence": "table/data: Comparison table of 8 clinical trials across 10 metrics including Trial, Intervention, Mechanism, RoA, Stage, Sample Size, BCG-Free Regimen, CR Any Time, CR 6 Mo, CR 12 Mo, and Safety Profile.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:45:06.037438+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 25, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "6124051b-033a-46a7-ae64-2a7fb05cceba", "evidence": "The slide is structured as a comparative matrix of clinical trial data across multiple competitors.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:02:46.649+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 25, "frameworkName": "comparison_table" } ], "arcBeats": [], "loops": [ { "to": 40, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed", "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').", "position": 0, "objective": "What are the consequences of not adopting Cretostimogene?", "confidence": 0.8, "extraction": { "at": "2026-07-16 22:43:26.509211+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 26, "type": "resolution", "title": "PIVOT-006 trial design slide.", "function": "plan_implementation", "rawType": "appendix_methodology", "block": null, "metadata": { "slideType": "appendix_methodology", "slideTypeCanon": { "name": "Appendix methodology", "slug": "appendix_methodology", "status": "active", "canonId": "019de52d-07d9-726c-8599-167f2d2ffaa7", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "dense", "densityScore": 67, "componentCount": 6, "textChars": 833, "nDataPoints": 0, "notes": "PIVOT-006 trial design slide.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:46.334+00", "seconds": 3.146, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/26", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-26", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.3 }, "kind": "diagram", "text": "Intermediate-Risk NMIBC -> Cretostimogene vs Observation -> RFS Rate", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:46.334+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0f893bce-ad8b-4b9c-9c52-df1766ed7d7d", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.6, "x": 0.05, "y": 0.9 }, "kind": "disclaimer", "text": "Maintenance course for complete responders weekly x 3 at month 3 and month 6, and once every 3 months at month 9 and month 12. Note: Patients undergo urine cytology and cystoscopy every 3 months for first 2 years; mandatory, site-directed biopsy at month 12.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:46.334+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "17a434e4-9332-4386-b371-bfdc13181362", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.3, "x": 0.38, "y": 0.45 }, "kind": "list", "text": "Study Design / Regimen: Arm A = Cretostimogene Following TURBT (Induction weekly x 6, Maintenance weekly x 3), Arm B = Observation Following TURBT", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:46.334+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6945566e-2171-4fed-aae7-7445254424d0", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.25, "x": 0.7, "y": 0.45 }, "kind": "list", "text": "Additional Endpoints: RFS at 12-month and 24-month, PFS, Safety", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:46.334+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "70a2a8ce-bd6f-480c-9867-3cc433e38d02", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.3, "x": 0.05, "y": 0.45 }, "kind": "list", "text": "Population: Pathologically confirmed Intermediate-Risk NMIBC (Recurrent LG Ta < 12mo, Solitary LG Ta > 3cm, LG Ta multifocal, HG Ta <= 3cm, LG T1), All disease removed by TURBT at baseline", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:46.334+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b8fa3193-fb3e-494a-adec-a44fa467ed02", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.9, "x": 0.05, "y": 0.1 }, "kind": "title", "text": "Phase 3 Adjuvant Cretostimogene Following TURBT Versus Observation Following TURBT for Intermediate Risk NMIBC", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:46.334+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "93a6812a-d271-4afb-a47e-e70bdc0ee51f", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "c9110b64-e1ad-47c1-9519-59c8e7c348dc", "evidence": "list/bullet: Population: Pathologically confirmed Intermediate-Risk NMIBC (Recurrent LG Ta < 12mo, Solitary LG Ta > 3cm, LG Ta multifocal, HG Ta <= 3cm, LG T1), All disease removed by TURBT at baseline", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:45:06.102279+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 26, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [ { "to": 40, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed", "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').", "position": 0, "objective": "What are the consequences of not adopting Cretostimogene?", "confidence": 0.8, "extraction": { "at": "2026-07-16 22:43:26.509211+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 27, "type": "setup", "title": "The slide uses a process-flow layout to define the clinical trial structure.", "function": "present_framework", "rawType": "appendix_methodology", "block": null, "metadata": { "slideType": "appendix_methodology", "slideTypeCanon": { "name": "Appendix methodology", "slug": "appendix_methodology", "status": "active", "canonId": "019de52d-07d9-726c-8599-167f2d2ffaa7", "version": 1, "description": null }, "function": "present_framework", "functionCanon": { "name": "Present framework", "slug": "present_framework", "status": "active", "canonId": "019de52d-1403-7667-9100-d2ac6709f750", "version": 1, "description": null }, "density": "dense", "densityScore": 73, "componentCount": 6, "textChars": 759, "nDataPoints": 4, "notes": "The slide uses a process-flow layout to define the clinical trial structure.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:47.181+00", "seconds": 3.687, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/27", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-27", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.88, "x": 0.06, "y": 0.31 }, "kind": "diagram", "text": "Population, Study Design / Regimen, Additional Endpoints", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:47.181+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "804a444c-da99-4c34-9e36-417cb237d2f6", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.55, "x": 0.06, "y": 0.93 }, "kind": "disclaimer", "text": "Second induction course of weekly x 6 for non-responders at month 3. Maintenance course for complete responders starts at month 3 every 3 months (weekly x 3) until disease recurrence. Note: Patients undergo urine cytology and cystoscopy every 3 months for first 2 years; mandatory, site-directed biopsy at month 12.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:47.181+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f115679b-6ed3-4fab-8c1e-0e4368e1fb10", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.33, "x": 0.37, "y": 0.49 }, "kind": "list", "text": "Cohort A = BCG-exposed NMIBC (Induction, Second induction, Maintenance); Cohort B = BCG-naïve NMIBC (Same regimen)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:47.181+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "12c4dd58-17e7-4583-a987-174979d0ddf1", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.21, "x": 0.73, "y": 0.49 }, "kind": "list", "text": "CR at 12 months; DoR; PFS", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:47.181+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "56524d24-420b-447a-b89c-59259a56ec13", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.28, "x": 0.06, "y": 0.049 }, "kind": "list", "text": "Pathologically confirmed high-risk NMIBC; BCG-exposed patients must have had prior BCG therapy; Have all Ta/T1 disease resected prior to treatment", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:47.181+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e1eb0fb1-573c-4244-a8d4-3085da2490e0", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.88, "x": 0.06, "y": 0.13 }, "kind": "title", "text": "Phase 2 Cretostimogene Monotherapy Study for High-Risk, BCG-Exposed and BCG-Naïve NMIBC (Planned Study)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:47.181+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "becfed37-dca7-41b9-855a-ad30a580c1b1", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "9298744e-81d1-420a-ac82-c4c1426e5261", "evidence": "list/bullet: Pathologically confirmed high-risk NMIBC; BCG-exposed patients must have had prior BCG therapy; Have all Ta/T1 disease resected prior to treatment", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:45:06.164789+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 27, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "b0a6e002-fccd-4acc-9cb7-950b6ab17143", "evidence": "The slide uses a three-column process flow to define the clinical trial methodology.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:02:47.181+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 27, "frameworkName": "process" } ], "arcBeats": [], "loops": [ { "to": 40, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed", "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').", "position": 0, "objective": "What are the consequences of not adopting Cretostimogene?", "confidence": 0.8, "extraction": { "at": "2026-07-16 22:43:26.509211+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 28, "type": "resolution", "title": "The slide uses a hierarchical tree structure to map patient risk categories to specific clinical trial programs (PIVOT-006, CORE-008, BOND-003, CORE-001).", "function": "size_opportunity", "rawType": "market_sizing", "block": null, "metadata": { "slideType": "market_sizing", "slideTypeCanon": { "name": "Market sizing", "slug": "market_sizing", "status": "active", "canonId": "019de52d-08c8-756c-8664-733b73a7ee7b", "version": 1, "description": null }, "function": "size_opportunity", "functionCanon": { "name": "Size opportunity", "slug": "size_opportunity", "status": "active", "canonId": "019de52d-147b-7568-8828-a74a27697618", "version": 1, "description": null }, "density": "dense", "densityScore": 63, "componentCount": 6, "textChars": 410, "nDataPoints": 6, "notes": "The slide uses a hierarchical tree structure to map patient risk categories to specific clinical trial programs (PIVOT-006, CORE-008, BOND-003, CORE-001).", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:47.326+00", "seconds": 3.785, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/28", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-28", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.4, "w": 0.9, "x": 0.05, "y": 0.45 }, "kind": "chart", "text": "Clinical trial program mapping to patient segments", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:47.326+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2144a2e2-9a85-4137-8b7d-2970cdae2ad7", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.9, "x": 0.05, "y": 0.26 }, "kind": "diagram", "text": "NMIBC (75%) (Non-Muscle Invasive Bladder Cancer)", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:47.326+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "14684f97-10b8-4e48-9727-e5c88dce3553", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.3, "x": 0.05, "y": 0.92 }, "kind": "legend", "text": "Current Program (black box) vs Planned Studies (orange box)", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:47.326+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b8acf6a0-c762-413b-b4ca-8eb269188e00", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.9, "x": 0.05, "y": 0.35 }, "kind": "list", "text": "Intermediate Risk (30%) vs High Risk (40%)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:47.326+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a6bcf64c-06ae-4c29-bc1f-6dadb3b07f71", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.18 }, "kind": "paragraph", "text": "All Bladder Cancer (U.S. Incidence ~82,000 Patients/Year; Prevalence ~725,000 Patients)", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:47.326+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a54263f4-e20f-4ca2-b6cf-e7527130e34a", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Focused Execution Towards Becoming the Leader in High-Risk and Intermediate-Risk Markets with Multi-Billion Dollar Potential", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:47.326+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ed813e15-57a0-4bc9-940f-836aa200e7a1", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "status": "active", "bestFor": null, "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae", "version": 1, "bodyDocId": null, "description": "Choosing the right chart type for your data and message", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "40380a79-e666-450f-a401-85ba5066ec9e", "evidence": "chart/bar-vertical: Clinical trial program mapping to patient segments", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:45:06.229745+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 28, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "6366e858-9526-4932-811c-df6bd1a73b25", "evidence": "Hierarchical breakdown of bladder cancer patients by risk and treatment status.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:02:47.326+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 28, "frameworkName": "market-segmentation-pyramid" } ], "arcBeats": [], "loops": [ { "to": 40, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed", "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').", "position": 0, "objective": "What are the consequences of not adopting Cretostimogene?", "confidence": 0.8, "extraction": { "at": "2026-07-16 22:43:26.509211+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 29, "type": "appendix", "title": "CMC stands for Chemistry, Manufacturing, and Controls.", "function": "plan_implementation", "rawType": "other", "block": null, "metadata": { "slideType": "other", "slideTypeCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-0af5-71ed-83de-d51ae245fc43", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "balanced", "densityScore": 44, "componentCount": 5, "textChars": 343, "nDataPoints": 0, "notes": "CMC stands for Chemistry, Manufacturing, and Controls.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:46.357+00", "seconds": 2.371, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/29", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-29", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.15, "x": 0.03, "y": 0.48 }, "kind": "image", "text": "CG Oncology", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:46.357+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4e841fad-9d1d-4ac2-91fc-f53495893f90", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.7, "x": 0.24, "y": 0.53 }, "kind": "list", "text": "Cretostimogene manufacturing process exhibits high yield & low COGS", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:46.357+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "243dc593-a018-4bc8-af94-56794f0b12a0", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.7, "x": 0.24, "y": 0.78 }, "kind": "list", "text": "Rapidly scalable process supports commercial demand in additional NMIBC market segments", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:46.357+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8e463dd2-a388-4a6c-9862-42a7d060ace3", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.7, "x": 0.24, "y": 0.28 }, "kind": "list", "text": "Current manufacturing scale supports commercial demand for our lead indication in BCG-unresponsive NMIBC", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:46.357+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c8986dd1-43a5-47f2-ac11-d191816827db", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.75, "x": 0.19, "y": 0.05 }, "kind": "title", "text": "CG Oncology is Preparing for Long-Term Commercial Demand of Cretostimogene", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:46.357+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cb4d6533-d90d-4a44-ac3a-fc017cbe1bd3", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "39792482-da04-4263-a895-b4eca7f34fd5", "evidence": "list/bullet: Current manufacturing scale supports commercial demand for our lead indication in BCG-unresponsive NMIBC", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:45:06.291359+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 29, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [ { "to": 40, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed", "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').", "position": 0, "objective": "What are the consequences of not adopting Cretostimogene?", "confidence": 0.8, "extraction": { "at": "2026-07-16 22:43:26.509211+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 30, "type": "setup", "title": "The slide uses a grid of four headshots with biographical details and company logos for each member.", "function": "other", "rawType": "team_bio", "block": null, "metadata": { "slideType": "team_bio", "slideTypeCanon": { "name": "Team bio", "slug": "team_bio", "status": "active", "canonId": "019de52d-0a7d-7394-ae5b-037478e71f1e", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "dense", "densityScore": 59, "componentCount": 7, "textChars": 355, "nDataPoints": 0, "notes": "The slide uses a grid of four headshots with biographical details and company logos for each member.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:47.394+00", "seconds": 3.354, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/30", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-30", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.2, "w": 0.2, "x": 0.55, "y": 0.2 }, "kind": "image", "text": "Dr. Richard Peluso, Ph.D.", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:47.394+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "541f770e-7731-4359-ac46-a2045f73d220", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.2, "x": 0.3, "y": 0.2 }, "kind": "image", "text": "Dr. Dan Takefman, Ph.D.", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:47.394+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5e0b67f8-eb14-4240-8c6b-4b15bafabc81", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.2, "x": 0.05, "y": 0.2 }, "kind": "image", "text": "Dr. Rick Rutter, Ph.D. (Chair)", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:47.394+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b3d3399f-6b6d-4f32-8748-dceba9666b37", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.2, "x": 0.8, "y": 0.2 }, "kind": "image", "text": "Dr. Victoria Sluzky, Ph.D.", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:47.394+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ff18b5ac-0075-41dc-99eb-25874a0c0d4f", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.9, "x": 0.05, "y": 0.45 }, "kind": "list", "text": "Biographical details for the four board members", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:47.394+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f2624eb5-e20b-4054-9d38-12fb523c036c", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.9 }, "kind": "title", "text": "Transformational Expertise in Biologics & Vaccines Manufacturing, Process Development, and Analytical Development", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:47.394+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4b6a73b6-5bd6-4bf4-b2b8-13e4d17f463c", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.8, "x": 0.1, "y": 0.05 }, "kind": "title", "text": "CG Oncology Established a CMC Advisory Board to Complement Strong In-House CMC Capabilities", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:47.394+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b5d31665-e7f8-42ee-a1ba-32d367af7c80", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Action Titles", "slug": "action-titles", "status": "active", "bestFor": "Any decision-grade deliverable — strategy recommendation, board update, investment memo, M&A review, post-mortem — where the reader is being asked to agree, decide, or act and will skim the title bar at speed.", "canonId": "019dd956-ac70-700b-a608-ba58e78f5dcc", "version": 1, "bodyDocId": "816dad3c-9983-41c1-a86e-978ebd582841", "description": "The McKinsey-bred discipline of writing every slide title as a complete declarative sentence with a verb and an insight, not a topic label. Each title is a sub-claim that ladders up to the deck's governing thought; read in sequence, the titles reconstruct the executive summary.", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "c01f1d3a-ee4b-4e3c-bbfa-acf6c406bf76", "evidence": "title/action-title: Transformational Expertise in Biologics & Vaccines Manufacturing, Process Development, and Analytical Development", "pageRefs": null, "priority": "Core", "whenToUse": "Any decision-grade deliverable — strategy recommendation, board update, investment memo, M&A review, post-mortem — where the reader is being asked to agree, decide, or act and will skim the title bar at speed.", "confidence": 0.9, "extraction": { "at": "2026-07-17 00:45:06.354986+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 30, "whyItWorks": "Solves two failure modes at once. (1) The buried claim: action titles place the conclusion on the page before any analysis is read, so a busy reader doesn't reverse-engineer it from the chart. (2) The spineless deck: because each title is a claim, slides have to ladder up to the governing thought; logical gaps become visible as topic-shaped titles in a sequence that no longer reads as a story.", "antipattern": "Topic labels disguised as titles — Volume by quarter, Key findings, Pricing strategy, Margins have been impacted. No verb, or a passive verb with no agent, or a fact (Revenue grew 12%) without the so-what. Also: titles that overreach the chart's evidence, multi-claim X-grew-but-Y-fell welded titles, and mechanical repetition of the same X-drove-Y template across the deck.", "cardinality": null, "narrativePurpose": "Forces the deck to carry its argument in the title bar so a senior reader can extract the recommendation without opening a single slide; converts a binder of topics into a navigable pyramid where every slide is a node defending the apex." } ], "frameworks": [], "arcBeats": [], "loops": [ { "to": 40, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed", "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').", "position": 0, "objective": "What are the consequences of not adopting Cretostimogene?", "confidence": 0.8, "extraction": { "at": "2026-07-16 22:43:26.509211+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 31, "type": "resolution", "title": "The slide uses a circular process flow graphic to represent a sequential commercialization strategy.", "function": "plan_implementation", "rawType": "go_to_market", "block": null, "metadata": { "slideType": "go_to_market", "slideTypeCanon": { "name": "Go-to-market", "slug": "go_to_market", "status": "active", "canonId": "019de52d-0ff6-713a-bd55-53d4e90b2304", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "balanced", "densityScore": 33, "componentCount": 4, "textChars": 293, "nDataPoints": 0, "notes": "The slide uses a circular process flow graphic to represent a sequential commercialization strategy.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:46.877+00", "seconds": 2.385, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/31", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-31", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.18, "x": 0.02, "y": 0.18 }, "kind": "diagram", "text": "Circular process flow with numbered steps 1-5", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:46.877+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c812f0b8-4264-49df-909a-6c1e77f7118f", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.15, "x": 0.025, "y": 0.465 }, "kind": "image", "text": "CG Oncology logo", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:46.877+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "25001ef4-ffeb-4b1a-a6fc-7ea907f23aca", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.55, "x": 0.22, "y": 0.21 }, "kind": "list", "text": "1. Prepare the market\n2. Drive sustainable product differentiation\n3. Establish optimal access and broad reimbursement\n4. Ensure unique and positive customer experience\n5. Launch when fully ready", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Numbered list", "slug": "numbered", "status": "active", "canonId": "019de52c-fcc0-7718-a284-a4250c805df2", "version": 1, "description": null }, "framework": null }, "subkind": "numbered", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:46.877+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "158b1605-90d3-4831-85bf-ce4f0ef2e604", "parentComponentId": null }, { "bbox": { "h": 0.045, "w": 0.565, "x": 0.188, "y": 0.065 }, "kind": "title", "text": "Cretostimogene Commercial Opportunity", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:46.877+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1976eba4-67dc-4ebb-a3b7-f84ab04615bc", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "4c9af711-db2e-460f-a111-bc35b3610d7a", "evidence": "list/numbered: 1. Prepare the market\n2. Drive sustainable product differentiation\n3. Establish optimal access and broad reimbursement\n4. Ensure unique and positive customer experience\n5. Launch when fully ready", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:45:06.418963+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 31, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "d1207622-4092-42a3-8986-f6c2ac792c40", "evidence": "Sequential numbered steps for commercialization", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:02:46.877+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 31, "frameworkName": "process" } ], "arcBeats": [], "loops": [ { "to": 40, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed", "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').", "position": 0, "objective": "What are the consequences of not adopting Cretostimogene?", "confidence": 0.8, "extraction": { "at": "2026-07-16 22:43:26.509211+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 32, "type": "resolution", "title": "The diagram uses a hub-and-spoke model to show how various commercial roles interact with the central customer entities (LUGPA and Hospitals).", "function": "plan_implementation", "rawType": "go_to_market", "block": null, "metadata": { "slideType": "go_to_market", "slideTypeCanon": { "name": "Go-to-market", "slug": "go_to_market", "status": "active", "canonId": "019de52d-0ff6-713a-bd55-53d4e90b2304", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "balanced", "densityScore": 30, "componentCount": 3, "textChars": 385, "nDataPoints": 0, "notes": "The diagram uses a hub-and-spoke model to show how various commercial roles interact with the central customer entities (LUGPA and Hospitals).", "elementsJson": null, "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:47.4+00", "seconds": 2.844, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/32", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-32", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.55, "w": 0.58, "x": 0.21, "y": 0.28 }, "kind": "diagram", "text": "Commercial organizational structure showing National Account Directors, Reimbursement Account Managers, Regional Business Directors, Territory Business Managers, and Medical Science Liaisons interacting with LUGPA and Hospitals.", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Hub and spoke", "slug": "hub-spoke", "status": "active", "canonId": "019de52d-04db-73e6-81ca-a234f2f23fc1", "version": 1, "description": null }, "framework": null }, "subkind": "hub-spoke", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:47.4+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ff27f1ac-8ceb-4222-9568-e1fdd66a635c", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.55, "x": 0.23, "y": 0.18 }, "kind": "title", "text": "Functions Aligned to Deliver Value to Customers and Patients", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:47.4+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0a93a85d-11f2-4aa0-bdde-213511251c38", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.75, "x": 0.18, "y": 0.03 }, "kind": "title", "text": "Cretostimogene Launch Strategy Focuses on Innovative & Agile Customer Engagement to Deliver Value", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:47.4+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "77cea75b-fbe2-4031-aaed-9c071fb507d5", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "b36b35da-4b9f-461d-86a7-aba7da604194", "evidence": "The visual arrangement of roles around a central customer entity.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:02:47.4+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 32, "frameworkName": "hub-spoke" } ], "arcBeats": [], "loops": [ { "to": 40, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed", "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').", "position": 0, "objective": "What are the consequences of not adopting Cretostimogene?", "confidence": 0.8, "extraction": { "at": "2026-07-16 22:43:26.509211+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 33, "type": "resolution", "title": "The slide uses a grid-based timeline layout to map specific clinical trial milestones (stars) against time periods.", "function": "plan_implementation", "rawType": "timeline", "block": null, "metadata": { "slideType": "timeline", "slideTypeCanon": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-0851-75eb-b758-ea2965e7739a", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "balanced", "densityScore": 38, "componentCount": 4, "textChars": 292, "nDataPoints": 1, "notes": "The slide uses a grid-based timeline layout to map specific clinical trial milestones (stars) against time periods.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:47.335+00", "seconds": 2.631, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/33", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-33", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.9, "x": 0.05, "y": 0.17 }, "kind": "chart", "text": "Clinical trial milestone grid", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": null, "framework": null }, "subkind": "timeline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:47.335+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "81e91cb2-a224-4d18-93bc-0600db161693", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.94 }, "kind": "disclaimer", "text": "1 Planned clinical trials... 2 Preliminary and unaudited estimate...", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:47.335+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "750a763d-d4fd-404d-8e96-1428d154cdb7", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.56, "x": 0.22, "y": 0.86 }, "kind": "metric", "text": "$187.7 million in cash, cash equivalents and marketable securities as of January 1, 2024", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:47.335+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "199ccb67-bb18-47e5-9df2-2221503c2f3b", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.78, "x": 0.19, "y": 0.03 }, "kind": "title", "text": "Catalyst Rich Calendar Through Potential First Approval and Launch Followed by Bladder Indication Expansion", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:47.335+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ac88c821-92f4-4b71-b8f5-62c3ba57956f", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "3927f3ba-8e87-4cb8-8344-0b66a6bf3c75", "evidence": "The slide uses a grid to map project milestones over time.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:02:47.335+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 33, "frameworkName": "gantt-chart" } ], "arcBeats": [], "loops": [ { "to": 40, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed", "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').", "position": 0, "objective": "What are the consequences of not adopting Cretostimogene?", "confidence": 0.8, "extraction": { "at": "2026-07-16 22:43:26.509211+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 34, "type": "resolution", "function": "summarize", "rawType": "key_takeaways", "block": null, "metadata": { "slideType": "key_takeaways", "slideTypeCanon": { "name": "Key takeaways", "slug": "key_takeaways", "status": "active", "canonId": "019de52d-06e7-7674-a891-9f7de3b11b6d", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "dense", "densityScore": 68, "componentCount": 7, "textChars": 582, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:51.351+00", "seconds": 6.44, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/34", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-34", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.15, "x": 0.05, "y": 0.2 }, "kind": "image", "text": "Numbered list graphic", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.351+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "74a06186-b5ab-4b9f-9d06-306779cd94e4", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.7, "x": 0.25, "y": 0.5 }, "kind": "list", "text": "Demonstrated clinical utility and observed tolerability drives further combination development strategies", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.351+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0074c5db-fa68-45e1-bddb-18e3ec8584a7", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.7, "x": 0.25, "y": 0.2 }, "kind": "list", "text": "Potential backbone oncolytic immunotherapy targeting a multi-billion dollar market opportunity in lead indication with significant unmet need", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.351+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "41ddc6dd-06ba-4b92-a9ce-8eb8a3d4bbf6", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.7, "x": 0.25, "y": 0.65 }, "kind": "list", "text": "Highly concentrated U.S. customer base enables focused execution in sales and marketing for commercialization", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.351+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "637e78ea-5896-4721-8417-d4fc7b0f396d", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.7, "x": 0.25, "y": 0.35 }, "kind": "list", "text": "Opportunity to expand into additional billion-dollar bladder indications", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.351+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8ba1ce5f-5ac3-43a4-9077-399314036bcb", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.7, "x": 0.25, "y": 0.8 }, "kind": "list", "text": "Experienced leadership team, seasoned CMC advisory board, and quality Life Sciences-focused investors", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.351+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c9694334-e498-4fd7-94f2-f21c7fdfc622", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.6, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "CG Oncology Investment Highlights", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.351+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ddc7c2c1-dfdf-4fec-a19d-ece7be41615d", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "c23a572e-f66b-4d85-8a08-8c9b07ff8303", "evidence": "list/bullet: Potential backbone oncolytic immunotherapy", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:44:58.0917+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 34, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [ { "to": 40, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed", "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').", "position": 0, "objective": "What are the consequences of not adopting Cretostimogene?", "confidence": 0.8, "extraction": { "at": "2026-07-16 22:43:26.509211+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 35, "type": "setup", "title": "This is a standard contact/footer slide often found at the end of a pitch deck.", "function": "front_matter", "rawType": "cover", "block": null, "metadata": { "slideType": "cover", "slideTypeCanon": { "name": "Cover", "slug": "cover", "status": "active", "canonId": "019de52d-05f2-729d-9f93-e0504f0a2410", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "balanced", "densityScore": 42, "componentCount": 6, "textChars": 180, "nDataPoints": 0, "notes": "This is a standard contact/footer slide often found at the end of a pitch deck.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:52.153+00", "seconds": 6.901, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/35", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-35", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.25, "x": 0.05, "y": 0.3 }, "kind": "image", "text": "CG Oncology", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.153+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d5085bdd-d1fa-4658-bd12-a2131eb2388b", "parentComponentId": null }, { "bbox": { "h": 1, "w": 0.5, "x": 0.5, "y": 0 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.153+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5af93789-818b-475e-b09c-f5cfb5304adc", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.2, "x": 0.28, "y": 0.75 }, "kind": "paragraph", "text": "MediaRelations@cgoncology.com", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.153+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "010423d1-775d-413d-af58-7f27687ead66", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.2, "x": 0.28, "y": 0.65 }, "kind": "paragraph", "text": "Information@cgoncology.com", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.153+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "576d4b36-4d77-4793-a56a-07b9a681e07b", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.2, "x": 0.07, "y": 0.65 }, "kind": "paragraph", "text": "CG Oncology Inc. 400 Spectrum Center Dr Suite #2040 Irvine, CA 92618", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.153+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "92deacbf-6069-4d64-b8b4-3fe3d09e126b", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.15, "x": 0.3, "y": 0.3 }, "kind": "paragraph", "text": "Attacking Bladder Cancer for a Better Tomorrow", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.153+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9f30c64c-f75f-468c-bcc6-63a3eb91a24f", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Slide recipe: Cover", "slug": "cover-slide", "status": "active", "bestFor": null, "canonId": "019df269-2a08-767d-9128-e7431e6fe8a3", "version": 1, "bodyDocId": "019df269-29e5-7738-b5fa-6892e5dc8e65", "description": "The first ten seconds. Build it deliberately.", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "e14956cd-4ee4-4a3b-98c2-02338e6aabee", "evidence": "CG Oncology Inc. 400 Spectrum Center Dr Suite #2040 Irvine, CA 92618", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:44:58.159907+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 35, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [ { "to": 40, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed", "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').", "position": 0, "objective": "What are the consequences of not adopting Cretostimogene?", "confidence": 0.8, "extraction": { "at": "2026-07-16 22:43:26.509211+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 36, "type": "tension", "function": "frame_problem", "rawType": "problem_statement", "block": null, "metadata": { "slideType": "problem_statement", "slideTypeCanon": { "name": "Problem statement", "slug": "problem_statement", "status": "active", "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4", "version": 1, "description": null }, "function": "frame_problem", "functionCanon": { "name": "Frame problem", "slug": "frame_problem", "status": "active", "canonId": "019de52d-13db-753e-ad70-e9b2d0dab398", "version": 1, "description": null }, "density": "dense", "densityScore": 60, "componentCount": 5, "textChars": 551, "nDataPoints": 3, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:48.809+00", "seconds": 3.381, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/36", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-36", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 1, "w": 0.4, "x": 0, "y": 0 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:48.809+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "04e725ff-7ffa-4061-a0f9-512a6db752ce", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.5, "x": 0.45, "y": 0.68 }, "kind": "list", "text": "Continual production shortages of BCG and patient aversion to radical cystectomy underscores a significant unmet medical need for alternative treatments in NMIBC", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:48.809+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4f9201cc-1077-4901-a6ae-ff486905162e", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.5, "x": 0.45, "y": 0.45 }, "kind": "list", "text": "Approximately 65% of patients either do not respond or eventually develop disease recurrence after first-line BCG therapy and failure to achieve a CR is associated with risk of disease progression", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:48.809+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b1575485-ae0e-4d97-be70-dd8bfb397b90", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.5, "x": 0.45, "y": 0.22 }, "kind": "list", "text": "Bladder cancer is a heterogenous disease with more than 82,000+ newly diagnosed cases in the U.S. in 2023 and estimated 725,000+ people living with the disease as of 2020", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:48.809+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d74d7797-53f6-429e-94f8-26705cede5f1", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.3, "x": 0.45, "y": 0.08 }, "kind": "title", "text": "What we are solving for:", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:48.809+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c703dc6f-ebdf-4900-b0b2-571b5b5821de", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 40, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed", "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').", "position": 0, "objective": "What are the consequences of not adopting Cretostimogene?", "confidence": 0.8, "extraction": { "at": "2026-07-16 22:43:26.509211+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 37, "type": "evidence", "title": "The slide provides a breakdown of intellectual property and regulatory protections for the company's product.", "function": "cite_precedent", "rawType": "appendix_disclosure", "block": null, "metadata": { "slideType": "appendix_disclosure", "slideTypeCanon": { "name": "Appendix disclosure", "slug": "appendix_disclosure", "status": "active", "canonId": "019de52d-07b2-7549-8e8b-932a19f6e616", "version": 1, "description": null }, "function": "cite_precedent", "functionCanon": { "name": "Cite precedent", "slug": "cite_precedent", "status": "active", "canonId": "019de52d-142b-714b-86d4-58aad7b568ec", "version": 1, "description": null }, "density": "balanced", "densityScore": 41, "componentCount": 4, "textChars": 292, "nDataPoints": 7, "notes": "The slide provides a breakdown of intellectual property and regulatory protections for the company's product.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:48.68+00", "seconds": 3.196, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/37", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-37", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.02, "w": 0.27, "x": 0.02, "y": 0.96 }, "kind": "disclaimer", "text": "1 Does not take patent term adjustment into consideration.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:48.68+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6b004cca-3307-4a21-928f-b8cf777f4dec", "parentComponentId": null }, { "bbox": { "h": 0.22, "w": 0.96, "x": 0.02, "y": 0.228 }, "kind": "table", "text": "Regulatory Exclusivity table showing U.S., Europe, Japan, and China exclusivity periods.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:48.68+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4ed6510f-b180-48db-a885-f185df013a8d", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.96, "x": 0.02, "y": 0.545 }, "kind": "table", "text": "Cretostimogene Patents table showing dates and patent details for 2036, 2037, and 2038.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:48.68+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5f5a86f6-55cc-4273-ab33-fafc8b027ab2", "parentComponentId": null }, { "bbox": { "h": 0.035, "w": 0.624, "x": 0.188, "y": 0.065 }, "kind": "title", "text": "Potential Protection Until 2038 with Regulatory Exclusivity", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:48.68+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "563c36cf-b316-4ab5-aa85-9c3c9d23bfb9", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "5cf13ccf-1d1d-457e-9d04-03c4dee3d0d2", "evidence": "Regulatory Exclusivity table showing U.S., Europe, Japan, and China exclusivity periods", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:44:58.262519+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 37, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [ { "to": 40, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed", "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').", "position": 0, "objective": "What are the consequences of not adopting Cretostimogene?", "confidence": 0.8, "extraction": { "at": "2026-07-16 22:43:26.509211+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 38, "type": "resolution", "title": "The slide uses a genetic map comparison to explain the mechanism of action.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 51, "componentCount": 5, "textChars": 477, "nDataPoints": 0, "notes": "The slide uses a genetic map comparison to explain the mechanism of action.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:48.055+00", "seconds": 2.535, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/38", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-38", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.35, "x": 0.11, "y": 0.7 }, "kind": "callout", "text": "E2F-1 promoter acts as a safety mechanism to selectively replicate and lyse Rb-defective tumor cells while avoiding healthy cells with intact Rb pathways.", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:48.055+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5f436b45-241b-4f7f-94b0-2765d43a336b", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.35, "x": 0.52, "y": 0.7 }, "kind": "callout", "text": "GM-CSF is a widely recognized potent stimulator of long-term anti-tumor activity which primes the immune system and induce systemic tumor-specific immunity.", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:48.055+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c92c9e91-bb54-4d14-897f-d8a31927ce42", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.85, "x": 0.08, "y": 0.25 }, "kind": "diagram", "text": "Genetic map comparison of Wild Type Ad 5 and Cretostimogene", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Value chain", "slug": "value-chain", "status": "active", "canonId": "019de52d-048a-769c-aad6-4abdde7ef317", "version": 1, "description": null }, "framework": null }, "subkind": "value-chain", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:48.055+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c4c88d55-0b05-4a2d-b60c-126b93f1a00e", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.2, "x": 0.08, "y": 0.87 }, "kind": "legend", "text": "Modification vs. Wild Type Ad 5", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:48.055+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "291ac628-ab4d-4065-89e0-ee2ff6b55768", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.94, "x": 0.03, "y": 0.05 }, "kind": "title", "text": "Cretostimogene Engineered to Promote Tumor Selectivity and Anti-Tumor Potency", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:48.055+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "80a83d6a-f313-4b26-9370-23cc6d5f8bb2", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 40, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed", "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').", "position": 0, "objective": "What are the consequences of not adopting Cretostimogene?", "confidence": 0.8, "extraction": { "at": "2026-07-16 22:43:26.509211+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 39, "type": "resolution", "title": "The slide uses a color-coded matrix to segment the patient population by risk profile.", "function": "size_opportunity", "rawType": "market_sizing", "block": null, "metadata": { "slideType": "market_sizing", "slideTypeCanon": { "name": "Market sizing", "slug": "market_sizing", "status": "active", "canonId": "019de52d-08c8-756c-8664-733b73a7ee7b", "version": 1, "description": null }, "function": "size_opportunity", "functionCanon": { "name": "Size opportunity", "slug": "size_opportunity", "status": "active", "canonId": "019de52d-147b-7568-8828-a74a27697618", "version": 1, "description": null }, "density": "balanced", "densityScore": 33, "componentCount": 4, "textChars": 296, "nDataPoints": 0, "notes": "The slide uses a color-coded matrix to segment the patient population by risk profile.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:52.921+00", "seconds": 7.131, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/39", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-39", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.03, "w": 0.6, "x": 0.08, "y": 0.89 }, "kind": "disclaimer", "text": "* All carcinoma in situ (CIS) are flat, high grade, aggressive disease and has increased risk of recurrence and progression.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.921+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d6b41c50-afc2-44a6-9d67-33e4f55606fc", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.65, "x": 0.13, "y": 0.82 }, "kind": "legend", "text": "High Risk, Intermediate Risk, Low Risk, N/A", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.921+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ab96d78e-e76b-4bf9-863d-7e2c918824e9", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.85, "x": 0.07, "y": 0.2 }, "kind": "table", "text": "Matrix of Grade, Frequency, Size, and Tumor Stage", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.921+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c5fbd6b1-5739-4f70-8a64-f7092f025de2", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.75, "x": 0.18, "y": 0.05 }, "kind": "title", "text": "High-Risk and Intermediate-Risk Disease Make Up ~70% of NMIBC Market Opportunity", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.921+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c7073444-19d1-4734-9ba9-badcc308b77b", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "4692e9b8-1d62-4ed5-b539-a9331f15d0e4", "evidence": "The slide uses a multi-dimensional grid to categorize disease risk levels.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:02:52.921+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 39, "frameworkName": "matrix-nxn" } ], "arcBeats": [], "loops": [ { "to": 40, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed", "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').", "position": 0, "objective": "What are the consequences of not adopting Cretostimogene?", "confidence": 0.8, "extraction": { "at": "2026-07-16 22:43:26.509211+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 40, "type": "tension", "title": "The slide uses a split-screen layout to frame the problem from two angles: supply-side shortage and clinical-side risk.", "function": "frame_problem", "rawType": "problem_statement", "block": null, "metadata": { "slideType": "problem_statement", "slideTypeCanon": { "name": "Problem statement", "slug": "problem_statement", "status": "active", "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4", "version": 1, "description": null }, "function": "frame_problem", "functionCanon": { "name": "Frame problem", "slug": "frame_problem", "status": "active", "canonId": "019de52d-13db-753e-ad70-e9b2d0dab398", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 91, "componentCount": 9, "textChars": 1325, "nDataPoints": 6, "notes": "The slide uses a split-screen layout to frame the problem from two angles: supply-side shortage and clinical-side risk.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:49.467+00", "seconds": 3.672, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/40", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-40", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.3, "w": 0.3, "x": 0.35, "y": 0.25 }, "kind": "callout", "text": "Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:49.467+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e8ad8d4a-313e-4786-b67b-8192707fe9ed", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.35, "x": 0.05, "y": 0.15 }, "kind": "list", "text": "In 2017, Merck unexpectedly became the sole supplier of TICE BCG in many countries around the world, including the United States. NCCN guidelines as well as AUA, SUO no longer recommend use of BCG therapy in intermediate-risk NMIBC. BCG is rationed and prioritized for high-risk NMIBC patients in many hospitals and clinics. PIVOT-006 is designed to assess cretostimogene in intermediate-risk patients to alleviate the need to prioritize treatment recipients and ration of BCG given its market shortage", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:49.467+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "673ad227-e864-47f9-934c-82ff32349285", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.35, "x": 0.6, "y": 0.15 }, "kind": "list", "text": "Without BCG, radical cystectomy is a treatment option offered to more patients. High readmissions, complications, morbidity and mortality. Affects multiple organ systems (GI, urinary, Sexual). Few patients undergo cystectomy due to preference and comorbidities. BOND-003 is designed to assess cretostimogene in high-risk patients to address patient aversion to removal of their bladder", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:49.467+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9e2b9f31-a8c6-4d1d-a201-13071ea5512e", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.12, "x": 0.84, "y": 0.7 }, "kind": "metric", "text": "2% - 5% Mortality Rate", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:49.467+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "09fc473d-5abe-46b0-9cdc-c8c8850a7e93", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.15, "x": 0.52, "y": 0.7 }, "kind": "metric", "text": "26% - 64% Complication Rate", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:49.467+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4057866c-0eed-4f8a-ba55-e64a6c3ddcb8", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.15, "x": 0.68, "y": 0.7 }, "kind": "metric", "text": "20% - 29% Readmission Rate", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:49.467+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "425f4e0b-0938-409b-b4a9-b126d7e922e6", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.92 }, "kind": "source-note", "text": "NCCN Guidelines – Bladder Cancer 2022. Maiboma et al 2021, Eur J Urol 28(28) 1-8. Merck & Co. Press Release – January 27, 2021. Donat et al. European Association of Urology 55(2009) 177-186. Berger et al. Canadian Urological Association July 2019.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:49.467+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "98bbb2a4-8e9b-4a12-b2fb-94eb7e199176", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.35, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Global BCG Shortage", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:49.467+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1ac88291-a937-44f9-a531-c08c114bfef0", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.35, "x": 0.6, "y": 0.05 }, "kind": "title", "text": "Radical Cystectomy", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:49.467+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e5206e73-2ba8-4ac2-bcc7-160866d0c930", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 40, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed", "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').", "position": 0, "objective": "What are the consequences of not adopting Cretostimogene?", "confidence": 0.8, "extraction": { "at": "2026-07-16 22:43:26.509211+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 41, "type": "setup", "title": "The slide uses a hierarchical flow chart to categorize patient populations for clinical trial consistency.", "function": "present_framework", "rawType": "appendix_methodology", "block": null, "metadata": { "slideType": "appendix_methodology", "slideTypeCanon": { "name": "Appendix methodology", "slug": "appendix_methodology", "status": "active", "canonId": "019de52d-07d9-726c-8599-167f2d2ffaa7", "version": 1, "description": null }, "function": "present_framework", "functionCanon": { "name": "Present framework", "slug": "present_framework", "status": "active", "canonId": "019de52d-1403-7667-9100-d2ac6709f750", "version": 1, "description": null }, "density": "balanced", "densityScore": 32, "componentCount": 3, "textChars": 416, "nDataPoints": 0, "notes": "The slide uses a hierarchical flow chart to categorize patient populations for clinical trial consistency.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:48.432+00", "seconds": 2.581, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/41", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-41", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.9, "x": 0.05, "y": 0.2 }, "kind": "diagram", "text": "Flowchart showing classification of NMIBC recurrence after BCG treatment", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:48.432+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "69dbcf82-0d72-4e97-892b-7a2313903b6f", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.8, "x": 0.05, "y": 0.95 }, "kind": "source-note", "text": "Roumiguie et al, European Urology Volume 82, Issue 1, July 2022, Pages 34-36. International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with BCG-exposed High-Risk NMIBC.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:48.432+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "958bf659-5df7-43de-bdb8-a08fff286a31", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Precise Definition of Disease State for NMIBC Patients is Imperative to Homogenize Patient Populations in Conducting Optimal Clinical Trials", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:48.432+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9d0ebb9f-778c-4ed5-afd1-5b1ca0f2b169", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "ee68c4f0-1c5a-41d2-955a-2f2c1b6aed57", "evidence": "Hierarchical flow chart categorizing patient states based on sequential criteria.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:02:48.432+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 41, "frameworkName": "decision-tree" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 42, "type": "setup", "title": "The slide compares monotherapy vs combination therapy clinical trial data.", "function": "compare_peers", "rawType": "comparison_table", "block": null, "metadata": { "slideType": "comparison_table", "slideTypeCanon": { "name": "Comparison table", "slug": "comparison_table", "status": "active", "canonId": "019de52d-0a06-73f8-8813-fe022fab1de2", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "balanced", "densityScore": 43, "componentCount": 3, "textChars": 488, "nDataPoints": 12, "notes": "The slide compares monotherapy vs combination therapy clinical trial data.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:48.924+00", "seconds": 2.96, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/42", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-42", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.6, "x": 0.03, "y": 0.94 }, "kind": "source-note", "text": "1 Second induction course of weekly x 6 for non-responders at month 3. 2 Maintenance course every 3 months for Year 1 and every 6 months for Year 2 and Year 3. 3 One patient resumed dosing of pembrolizumab after missing a single dose.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:48.924+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c75de10b-62c8-403d-bc0e-91837a77e5ab", "parentComponentId": null }, { "bbox": { "h": 0.75, "w": 0.94, "x": 0.03, "y": 0.17 }, "kind": "table", "text": "Comparison table of BOND-003 and CORE-001 trials across trial, intervention, population, design, sample size, dosing, CR rates, and safety.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:48.924+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6c52f6c8-61c1-40f9-a9b1-72096f95ca86", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.75, "x": 0.18, "y": 0.05 }, "kind": "title", "text": "Advancing Our Highly Differentiated Product Candidate for Patients with BCG-Unresponsive NMIBC in Mono and in Combo", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:48.924+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cb1e6d07-b541-425a-bff0-801cd414b98b", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 43, "type": "setup", "title": "The slide explicitly notes that these are not head-to-head studies and differences in study design exist.", "function": "compare_peers", "rawType": "comparison_table", "block": null, "metadata": { "slideType": "comparison_table", "slideTypeCanon": { "name": "Comparison table", "slug": "comparison_table", "status": "active", "canonId": "019de52d-0a06-73f8-8813-fe022fab1de2", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "balanced", "densityScore": 47, "componentCount": 3, "textChars": 577, "nDataPoints": 24, "notes": "The slide explicitly notes that these are not head-to-head studies and differences in study design exist.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:49.944+00", "seconds": 3.804, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/43", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-43", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.03, "w": 0.75, "x": 0.02, "y": 0.93 }, "kind": "source-note", "text": "These data are not based on head-to-head or comparator studies. Differences exist between study designs and subject characteristics, and caution should be exercised when comparing data across studies. From published data. Disease-Free Survival estimated from Kaplan-Meier Analysis.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:49.944+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4ce1ccb7-5623-4509-95dc-882ac2a9e7c9", "parentComponentId": null }, { "bbox": { "h": 0.68, "w": 0.96, "x": 0.02, "y": 0.22 }, "kind": "table", "text": "Comparison table of Trial, Intervention, Mechanism, RoA, Stage, Sample Size, Median DFS, Follow-Up Duration, DFS at 12-Month, DFS at 24-Month, and Safety Profile for three drugs.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:49.944+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0eca19b1-724f-44e2-9d94-cb1696cb4eb6", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.75, "x": 0.19, "y": 0.04 }, "kind": "title", "text": "Clinical Profile of Therapeutic Agents in BCG-Unresponsive NMIBC High Grade Papillary Disease by Kaplan-Meier Analysis", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:49.944+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "94223088-98bd-4ba3-a01f-3acdeb141d4b", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "e8258989-ebb6-45b9-bf35-ecc46ee5330a", "evidence": "Structured data comparison across three clinical trials.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:02:49.944+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 43, "frameworkName": "comparison_table" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 44, "type": "analysis", "title": "The slide highlights the safety profile, emphasizing that most AEs are low-grade and transient.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 79, "componentCount": 7, "textChars": 619, "nDataPoints": 44, "notes": "The slide highlights the safety profile, emphasizing that most AEs are low-grade and transient.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:53.099+00", "seconds": 6.509, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/44", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-44", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.25, "x": 0.38, "y": 0.85 }, "kind": "callout", "text": "No grade 4 or 5 events related to cretostimogene were reported", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:53.099+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5a43c099-d14e-43cf-97d7-0bad7cf04da3", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.25, "x": 0.05, "y": 0.85 }, "kind": "callout", "text": "Nearly all AEs transient Grade 1-2 local urinary tract symptoms", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:53.099+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6722798a-aea5-4cee-b010-efa312ce3ebe", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.25, "x": 0.7, "y": 0.85 }, "kind": "callout", "text": "No SAE event related to cretostimogene was reported", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:53.099+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a6013237-fdb0-439e-b5c9-f28774320906", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.3 }, "kind": "paragraph", "text": "Top Adverse Events Considered Related to Cretostimogene Administration for all Patients (n=68)¹ by Grade", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:53.099+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d9c74360-76fd-46ef-bb1a-df5e38c01e84", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.9, "x": 0.05, "y": 0.96 }, "kind": "source-note", "text": "¹ Includes 3 additional patients to N=65, 2 of which were Compassionate Use under IND12154 approved for treatment by FDA and 1 of which was determined to not have NMIBC CIS-containing disease at baseline.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:53.099+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5a730f7f-f943-4743-8d35-0330f40e51a4", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.9, "x": 0.05, "y": 0.38 }, "kind": "table", "text": "Table of adverse events by grade (1, 2, 3, All Grades)", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:53.099+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "63b40a92-4251-43f2-894b-e6da3fba4870", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.15 }, "kind": "title", "text": "Phase 2 Cretostimogene Monotherapy for High-Risk, BCG-Failure NMIBC (NCT02365818)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:53.099+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5c2b3ffc-543c-4c33-ba27-3af74cb6227e", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "0512c880-f250-496f-a68a-b8787451a199", "evidence": "Table of adverse events by grade (1, 2, 3, All Grades)", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:44:58.537907+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 44, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 45, "type": "setup", "title": "The slide uses a structured table format to categorize achievements into three pillars: Clinical, Corporate, and Financing.", "function": "summarize", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "dense", "densityScore": 72, "componentCount": 6, "textChars": 855, "nDataPoints": 1, "notes": "The slide uses a structured table format to categorize achievements into three pillars: Clinical, Corporate, and Financing.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:50.028+00", "seconds": 3.441, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/45", "deck": "/decks/019de076-f978-76c3-9c95-6b6ce7102162", "deckAnchor": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-45", "deckJson": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.14, "x": 0.03, "y": 0.05 }, "kind": "callout", "text": "At a Glance", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:50.028+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f1691758-ae09-4384-a5f7-3f93a0124cad", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.92, "x": 0.05, "y": 0.3 }, "kind": "list", "text": "Clinical: Completed enrollment ahead of schedule in Phase 3 Cretostimogene monotherapy trial in BCG-unresponsive NMIBC (BOND-003) with topline monotherapy data released at SUO Conference in Dec 2023; Announcement of positive topline Phase 2 Cretostimogene combo data in BCG-unresponsive NMIBC (CORE-001) in May 2023", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:50.028+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a3cba69e-5a46-45cd-867c-95d440414519", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.92, "x": 0.05, "y": 0.58 }, "kind": "list", "text": "Corporate: New additions to our Executive Leadership Team and Senior Leadership Team to develop and commercialize Cretostimogene to be the backbone therapy for NMIBC", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:50.028+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e937b84e-3478-459a-b9ba-88012c66c2e4", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.92, "x": 0.05, "y": 0.78 }, "kind": "list", "text": "Financing: Raised $225M led by quality Life Sciences-focused investors including ABG, Acorn Bioventures, Avidity Partners, BVF, Decheng Capital, Foresite Capital, Janus Henderson, Longitude Venture Partners, ORI Capital, RA Capital and TCG Crossover", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:50.028+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "eb004401-0f56-44b5-8a77-9158453e9271", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.75, "x": 0.19, "y": 0.03 }, "kind": "title", "text": "CG Oncology is Meaningfully Positioned to Become the Leading Company in Bladder Cancer", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:50.028+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a006849e-1b04-4add-95ad-0fbb206a5707", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.74, "x": 0.23, "y": 0.19 }, "kind": "title", "text": "Key Value Creation Since 2022", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "019de52c-fb09-739d-900c-815b0d9ac526", "version": 1, "description": null }, "framework": null }, "subkind": "subtitle", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:50.028+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "233c6475-6dee-4f14-bd5f-f0605fa9a34d", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "328ac865-deb6-4175-ae7e-0ebfc05c7c0d", "evidence": "The slide is titled 'CG Oncology is Meaningfully Positioned to Become the Leading Company in Bladder Cancer' and includes a section titled 'At a Glance'.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:44:59.288823+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 45, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true } ], "arcBeats": [ { "from": 11, "to": 11, "label": "Problem", "description": "Slide 11 presents the problem statement: 'Bladder Cancer is a Significant Unmet Medical Need Well Positioned for Innovation and Disruption'." }, { "from": 7, "to": 10, "label": "Solution", "description": "Slides 7-10 present the solution: 'Cretostimogene Grenadenorepvec Selectively Targets Rb-Pathway Defective Cancers' and its mechanism of action." }, { "from": 12, "to": 12, "label": "Market Size", "description": "Slide 12 presents the market sizing: 'NMIBC Represents a Multi-Billion Dollar Market Opportunity in Bladder Cancer'." }, { "from": 18, "to": 19, "label": "Traction", "description": "Slides 18-19 present traction: 'First Results From BOND-003: 75.7% CR at Any Time' and 'SUO 2023: First Results from BOND-003'." }, { "from": 4, "to": 4, "label": "Team", "description": "Slide 4 presents the team: 'The CG Oncology Team'." } ], "loops": [ { "from": 11, "to": 40, "label": "Cost Of Inaction", "description": "What are the consequences of not adopting Cretostimogene?" }, { "from": 13, "to": 15, "label": "Jobs To Be Done", "description": "What are the needs of patients with bladder cancer?" } ] }